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ABSTRACT 
Natural killer (NK) cells have a key role in control and clearance of viral infections. To carry 
out this function NK cells are capable of recognising infected cells and responding with 
induction of apoptosis in these cells, and production of pro-inflammatory cytokines. Target 
cells are recognised through various stress or infection related activating signals alongside 
‘missing self’ recognition of down-regulation of human leukocyte antigen molecules. 
Additional stimulation for NK cells comes in the form of the type I interferon (IFN), IFN-α, 
which is released by infected cells and the immune system’s sentinels, the dendritic cells (DC). 
As well as stimulating NK cells, IFN-α induces an anti-viral state in cells through up-
regulation of expression of IFN-stimulated genes. 
Infections with hepatitis B, C, and δ viruses (HBV, HCV, HDV) cause viral hepatitis and are 
major risk factors for developing liver fibrosis. Despite these infections causing similar clinical 
manifestations, and until recently treatment for all three utilising IFN-α, these three viruses 
differ greatly. Human immunodeficiency virus (HIV) is the causative agent of acquired 
immune deficiency syndrome (AIDS). This disease is characterised by loss of CD4 expressing 
cells resulting in a diminished immune system that leaves the host susceptible to 
opportunistic infections. HIV-1 is the cause of the AIDS pandemic, while HIV-2 associates 
with a slower disease progression. 
Each of these viruses is able to cause chronic infection. Part of the pathology of chronic 
infection, particularly HIV infection, is persistent immune activation and microbial 
translocation. In attempting to clear the infection the immune system can become perpetually 
activated, a condition associated with immune dysfunction. During this phase the immune 
response can contribute to disease progression through off-target effects, or appear as 
exhausted and dysfunctional. 
In this thesis I will show that the phenotype and function of NK cells are altered during 
infection, primarily dependent upon the stage of hepatitis infection irrespective of infecting 
virus. For HIV infections NK cell activation is dependent upon the level of viral replication. 
During IFN-α therapy for hepatitis infections there is an increase of the chronic inflammation 
and microbial translocation marker sCD14, while NK cell function is altered due to 
fluctuations in intracellular STAT signalling. 
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1 INTRODUCTION 
Infection with some microorganisms leads to disease [1], and our bodies’ way of fighting 
these pathogens is with the immune system [2,3] Unlike most human systems such as the 
nervous system consisting of the brain, spinal cord, and peripheral nerves, the immune 
system is not made from specific tissue or composed of a few large organs. Rather the 
immune system is formed from the lymphatic system, white blood cells (leukocytes), and 
complement proteins found throughout the body. 
The term immunity derives from the Latin immūnis (meaning exempt from tribute or 
taxation [4]), however the functions of the immune system go beyond protecting us from 
disease. Thought leukocytes are known to play parts in reproduction and development [5,6], 
and homeostasis [7-9], the immune system is primarily seen as the system for fighting 
pathogens. In performing this function it utilises many different leucocytes. All leucocytes 
derive from the haematopoietic stem cell (HSC) (Fig. 1), and will go on to permeate every 
system and organ in our body to varying degrees. 
 
Figure 1: Lineage of leukocytes in the Immune System 
The immune system was traditionally separated into two factions: innate and adaptive. These 
terms have blurred over the years with a number of leukocytes displaying both innate and 
adaptive features [10-12]. When responding to pathogens the immune system has a spectrum 
of defence mechanisms at its disposal, and deployment of these is dependant upon the 
microbe encountered [13-15]. Leukocytes also exhibit different functions depending upon the 
organ in which they reside [16-18]. 
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The immune response is therefore restricted in some instances. In the intestines, for example, 
immediate aggressive responses to gut microbiota would be counterproductive and so the 
immune system has a degree of tolerance [19,20]. Furthermore, along with pathogens causing 
disease themselves, some diseases can be caused or exacerbated due to excessive or 
inappropriate immune responses [21,22]. 
1.1 IMMUNOLOGY 
During initial development from the HSC, leukocytes split into either myeloid or lymphoid 
cells [23-25]. The myeloid basophils and eosinophils are involved in defence against parasites, 
while neutrophils are involved in bacterial defence. There are two different types of dendritic 
cell (DC) [26]; the myeloid DC (mDC) is primarily involved in detecting bacterial or viral 
infections and initiating adaptive immune responses [27], while plasmacytoid DCs (pDC) 
also detect infections and are a major source of type I interferon (IFN) [27]. Monocytes are 
able to mature into macrophages, a phagocytic cell type, and the mDC. 
Lymphoid cells include B cells, which following stimulation can develop into antibody 
producing plasma cells. T cells that have diverse functions as helpers, regulators and effectors 
of the immune system, and some pDCs are derived from the common lymphoid progenitor 
[28]. Also of lymphoid origin are the innate lymphoid cells (ILCs) [29], comprising lymphoid 
tissue inducers that are involved in the formation of lymph nodes, ILCs 1-3 [7] that help 
direct the immune response depending upon stimulus, and natural killer (NK) cells that are 
capable of directly killing transformed cells and producing inflammatory cytokines [30,31]. 
Virtually every cell in our body has some role to play in immunity to pathogens. Most cells 
will display what type of proteins they contain through the major histocompatibility complex 
(MHC) class I antigen presentation pathway [32]. MHC class I molecules are able to present 
peptides to the T cell receptor (TCR) of T cells, if a self-peptide is presented the T cell will 
generally not react, as they have gone through a tolerogenic selection process [33] and are not 
receiving any additional inflammatory signals. However if the peptide is non-self, and there is 
an additional inflammatory stimulus, then the T cell will become active and kill the target 
[34]. 
MHC class II proteins are expressed by major antigen-presenting cells such as DCs and 
macrophages, which are specialised in presenting antigens from the extracellular 
environment. The captured pathogens are broken down inside the cell and the peptides 
loaded onto the MHC class II molecules for display on the cell surface [35]. Upon engulfing 
the pathogen, the DC will mature and head to a local lymph node to initiate an adaptive 
immune response [36].  
Whilst MHC molecules present peptides, additional MHC-like molecules can present 
different cellular products. MR1 molecules present vitamin B2 metabolites to the recently 
discovered mucosa-associated invariant T (MAIT) cells [37,38], while CD1 molecules display 
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glycolipids to the TCR of natural killer T (NKT) cells [39]. MAIT cells have a semi-invariant 
TCR, as do type II NKT cells, whereas type I NKT cells have an invariant TCR and are often 
referred to as iNKT cells [40]. Together with their rapid response to infection, the invariant 
TCRs of both MAIT and NKT cells instils them with innate characteristics [41], and they can 
help induce and regulate the adaptive immune responses. 
Adaptive immunity generally refers to a response involving rearrangement of genetic material 
in a leukocyte, commonly B and T cells. These adaptive cells can further develop into memory 
cells which are capable of a specific and relatively fast immune response upon repeat 
infections [42]. Innate cells tend to be short lived and do not undergo such gene 
rearrangements. However, it appears that innate cells can possess memory characteristics 
caused by alterations of the cells’ epigenetics, sometimes referred to as training [43,44]. 
1.1.1 Viral Infection Response 
If a virus penetrates the frontline defences of skin or mucosa and infects a cell, the immune 
system has multiple methods to initially recognize an infection, and then attempt to clear the 
infection. Our cells utilize a litany of receptors that recognize pathogen associated molecular 
patterns (PAMPs), and damage associated molecular patterns (DAMPs) called pattern 
recognition receptors (PRRs) [45-47], which can either be membrane bound or intracellular. 
There are different families of these receptors – Toll-like receptors (TLRs) [48], C-type lectin 
receptors (CLRs) [49], nucleotide-binding oligomerisation domain (NOD)-like receptors 
(NLRs) [50], and retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs) [51,52]. Each of 
these is used in the identification of some pathogenic motif such as double stranded RNA or 
un-methylated CpG motifs in DNA that are associated with viruses. Signalling of the PRRs 
leads to a cascade of molecular interactions resulting in the induction of anti-viral responses 
[53], dependent upon which PRR is activated. 
DCs endocytose bacteria and viral particles from their surrounding environment to present 
their peptides to CD4+ T cells via MHC class II [35], or to CD8+ T cells with MHC class I 
molecules [54]. Upon the proteolytic degradation of microorganisms in the endosomal 
compartment, various parts of the genetic material are exposed to TLRs. TLR3 will detect 
double stranded RNA and signal via TRIF to activate interferon regulatory factor 3 (IRF3) 
[55-57]. TLR7 recognizes single stranded RNA [58], and TLR9 binds CpG islands on DNA 
[59]. Both signal through MyD88 to activate IRF5 and IRF7 [60,61]. All these IRFs will 
translocate to the nucleus of the cell to induce the production of type I IFNs [57,62] (Fig. 2). 
Viral infection and replication in cells will lead to the presentation of viral peptides via MHC 
class I proteins, which can be engaged by CD8+ cytotoxic T cells specific for that peptide [63]. 
Additionally PRRs on the surface of cells can also induce activation of IRFs, while cytosolic 
PRRs can induce a form of controlled cell death (apoptosis) of the infected cell via caspase 3 
[64]. In these ways viruses are able to be readily recognized, resulting in protective 
mechanisms of involving IFN production, signalling to cytotoxic cells, and apoptosis of 
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infected cells. However, many viruses have evolved to evade the immune system by 
disrupting many of these mechanisms such as causing down-regulation of MHC class I 
[65,66] or CD1 [67], and interfering with IFN signalling [68,69]. 
Figure 2: Virus induction of IFN-α production via various TLRs 
1.1.2 Liver Immunology 
All organs in the body have their own unique microenvironment in which the immune 
system operates. The liver not only takes blood from the circulation and removes toxins, but 
also receives blood from the gut via the portal vein. Incoming blood from the gut contains 
bacterial products, which under normal circumstances need to be tolerated lest you get a 
strong inflammatory response in the liver that would cause damage and possibly lead to 
fibrosis.  
Despite being a rather homogenous organ, the liver performs a large range of functions, 
including but not limited to bile production, glycogen storage, and blood detoxification. 75% 
of the livers blood supply originates from the gut via the portal vein, with the remaining 
quarter from the hepatic artery. Blood enters the sinusoidal spaces, from portal triads, and 
leaves via the hepatic vein (Fig. 3), allowing the blood plasma and associated soluble factors to 
permeate into the liver tissue. 
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Figure 3: Sinusoidal space in the liver 
Many different immune cell types reside in the liver, including Kupffer cells (the 
macrophages of the liver), DCs, MAIT cells, ILCs, and NK cells [70] (Fig 3). The liver 
sinusoidal endothelial cells (LSEC) help create a tolerogenic environment through their 
constitutive production of transforming growth factor (TGF)-β and interleukin (IL)-10 [71], 
thus any antigenic material that the DCs digest and present will culminate in the induction of 
regulatory T cells. TGF-β and IL-10 also induce tolerance in Kupffer cells, and NK cells [71-
74], however their effect on the MAIT cells is unknown.  
Although maintenance of a tolerogenic hepatic state is necessary, it is still important that the 
balance can be tipped in favour of an inflammatory response when there is an infection. To 
ensure this can happen the sinusoidal cells and hepatocytes express many PRRs [70,75] so 
that an infection can be readily detected, and production of pro-inflammatory cytokines can 
occur. Thus, with mDCs, pDCs, and Kupffer cells constantly sampling the environment, 
tolerogenic DCs can be induced to mature and, particularly pDCs, produce IFN-α [28,76]. 
During clearance of a viral infection the liver may be damaged due to destruction of 
hepatocytes, by either a cytopathic virus or non-specific killing caused by cytotoxic CD8+ T 
cells and NK cells [77]. If the infection can be cleared in a timely fashion then the damage will 
be limited and due to the regenerative capacity of the liver [78,79], will be repaired in time. 
On the other hand, if the infection and killing persists, then in place of the hepatocytes the 
hepatic stellate cells will lay down extracellular matrix (fibrotic tissue) [80,81]. With enough 
build up of the fibrotic tissue, a patient will develop fibrosis that may develop into to cirrhosis 
(Fig. 4). 
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Infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) are significant risk factors 
for the development of liver cirrhosis; in turn cirrhosis is a major risk factor for developing 
hepatocellular carcinoma (HCC). Effective therapy of hepatitis viral infections can lead to a 
reversal of fibrosis and cirrhosis [82,83]. However, removal of the underlying infection does 
not completely abate the risk of HCC development [84-86].  
 
Figure 4: Progression from viral infection to fibrosis 
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1.2 INNATE IMMUNE RESPONSES 
Immunity to viruses first involves barriers to infection such as skin or mucus and 
immunoglobulin (Ig) A. If a virus can survive or bypass these barriers through for example a 
cut (which it-self can produce a response by signalling DAMPs) then recognition of a virus is 
paramount to initiating a response. There are numerous PRRs, such as TLRs, that can 
recognize various non-self signatures. Most cells in the body also present what proteins they 
produce via the MHC molecules. After recognition of a viral threat, type I IFNs including 
IFN-α will be produced to induce anti-viral responses in the local environment, and activate 
immune cells that can kill virally infected cells such as NK cells. 
1.2.1 Interferon α 
IFNs were first identified as secreted proteins which were capable of interfering with 
influenza virus infections [87]. A major player in anti-viral responses, immune activation and 
hepatitis therapies is the type I IFN, IFN-α. When PRRs detect an infection they can lead to 
the production of IFN-α, additionally pDCs produce large quantities of IFN-α during 
infections [88,89]. IFN-α will help produce an anti-viral state by stimulating surrounding cells 
to induce interferon-stimulated genes (ISGs) [62,89], and activate NK cells [90]. Until very 
recently IFN-α was the mainstay of treatment for HCV [91], and despite hopes of new 
therapies is still used in treatment of HBV and hepatitis δ virus (HDV) infections [92-94]. 
IFN-α signals through a heterodimer receptor complex, consisting of the subunits IFN-α 
receptor 1 (IFNAR1) and IFNAR2. Binding of the receptor triggers an intracellular signalling 
cascade involving the JAK/STAT pathway culminating in the formation of IFN-stimulated 
gene factor 3 (ISGF3) that moves to the nucleus to induce ISGs [95] (Fig. 5). General effects of 
the ISGs are to increase expression of PRRs, and antiviral effectors that will inhibit viral entry 
and replication [62,89]. Exact functions enhanced by induction of the ISGs are dependent 
upon which and what concentrations of the 13 IFN-α subtypes bind the receptor, and the 
affinity of the binding [96]. Hence in this way an immune response can be fine-tuned. 
1.2.2 Natural Killer Cells 
A part of the wider ILC family [7], natural killer (NK) cells are an early responding 
lymphocyte important for cytotoxicity and pro-inflammatory cytokine production. NK cells 
were originally described over 40 years ago for their ability to kill tumour cells without any 
prior sensitization [97,98]. It would be another decade before the use of Leu-19 (NCAM-1, 
and henceforth CD56) to positively identify the majority of NK cells [99-101] superseding the 
use of HNK-1 (CD57) [102,103], which was also present on a large population of T cells.  
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 Figure 5: IFN-α induction of IFN-stimulated genes 
 
Based upon their expression level of CD56, NK cells are traditionally split into CD56bright and 
CD56dim subsets [104]. It is currently a matter of some debate if these are two separate lineages 
of NK cells [105,106] or if the CD56bright NK cells mature into the CD56dim NK cells [107-110]. 
Although these subsets are both capable of releasing cytokines and cytotoxicity, CD56bright NK 
cells do respond more readily to cytokine stimulation and the CD56dim NK cells to cellular 
activation [107,111-113]. A third NK cell subset, lacking CD56 expression, has been observed 
in viremic human immunodeficiency virus (HIV) and HCV infections [114,115]. This 
CD56neg NK cell subpopulation is also present in healthy individuals but in a much lower 
frequency. The function, and origin of these NK cells are still under investigation [116]. 
NK cells develop from the common lymphoid progenitor partially through the action of the 
transcription factors (TF) EOMES and T-bet [117-119]. Recent literature suggests that 
EOMES is an important TF with regards to NK cell cytotoxicity and can be used to help 
segregate NK cells from ILC-1, while T-bet is involved in cytokine production [119,120]. 
Given that NK cells do not require previous encounters with a target to be able to perform 
their cytotoxic function, the requirements for NK cell activation were unclear until the 
proposal of the ‘missing self’ hypothesis [121]. Here it was proposed that the hosts MHC 
molecules actively inhibit NK cells. When such self-MHC molecules are missing, due to viral 
infections or tumour transformation, the NK cells are no longer inhibited and will kill their 
target. Subsequent studies revealed that NK cell activation comes about through the 
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integration of a plethora of inhibitory and activating signals, be they cell-cell interactions, 
cytokines, or antibody recognition [122-124]. 
Major inhibitory pathways for NK cells include the cell surface killer immunoglobulin-like 
receptors (KIR) and NKG2A, whose ligands are indeed MHC class I molecules. The cytokines 
IL-10 and TGF-β have also been implicated in NK cell inhibition. Common activating cellular 
receptors include natural cytotoxicity receptors (NCR), NKG2C, NKG2D, DNAM-1, and 
some KIRs, with MHC class I molecules again acting as ligands alongside various stress-
induced molecules like MIC-A. Pro-inflammatory cytokines IFN-α, IL-12, and IL-18 are also 
potent activators of NK cells. In addition CD56dim and CD56neg NK cells have the IgG Fc 
receptor CD16. Activation leading to a functional response is dependent upon which 
combinations of receptors are stimulated [125,126], and prior epigenetic reprogramming 
[127,128]. 
There is the potential for a multitude of receptor combinations on NK cells, and with 
advancing technology it has been shown that if you were so inclined, NK cells could be 
subdivided into thousands of subsets [129]. Presumably, each potential subset will react 
slightly differently depending upon their receptor combination, the stimulus they receive, and 
the environment in which they find themselves. This wide range of receptor combinations 
does appear to diminish as a person grows older, hypothesized to be due to the number of 
infections encountered over the course of your lifetime [130]. 
The potential strength of NK cells responses can be altered by the inhibitory receptors on 
their surface in a series of processes termed education/licensing/arming/tuning [131-134]. 
During NK development, interaction of an inhibitory receptor NKG2A, KIR etc. with its 
cognate ligand will functionally mature the NK cell. This allows for an increased level of 
activation, if the cell can overcome the increased inhibition. Those NK cells that lack either 
the inhibitory receptor or cognate ligands still play an important role in controlling viral 
infection [135]. Expression of the KIRs is a stochastic event [136,137] that will ultimately tune 
the NK response [134,138]. 
1.2.3 NK Cell Functions 
Due to the uniqueness of their activation pathway, NK cells are important in early cytopathic 
response to transformed cells such as cancerous or virally infected cells. Their most evident 
responses are release of IFN-γ and their cytotoxic response. Following recognition of a target 
cell [126] and lacking inhibition [139], NK cells will form an immunological synapse 
[140,141], into which they will release perforin [142] and granzyme B (GzB) [141] (Fig. 6). 
Perforin perforates the cell, while GzB [143] enters the target and initiates apoptosis 
[144,145]. NK cells are also able to induce apoptosis in target cells through use the tumour 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), and Fas-ligand [146]. 
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Figure 6: NK cell interaction with infected target cell 
 
Recognition of IgG, produced by plasma cells, by CD16 is another important pathway in NK 
cell activation, as it does not require additional stimulation. Once activated via CD16, NK 
cells will perform antibody-dependent cell-mediated cytotoxicity (ADCC) [147], irrespective 
of their education [148]. Thus this function forms a part of the B cell adaptive response. 
NK cells have a number of key roles during viral infections [149], including hepatitis and HIV 
infections that shall be discussed in detail later. Although the major function of NK cells is to 
kill targets, it is the nature of the target that defines the role they play in immune responses. 
By targeting CD4+ helper T cells [150], and CD8+ cytotoxic T cells [151], NK cells are able to 
halt the adaptive immune response, an effect that can be avoided with type I IFN [152,153]. 
NK cells can further regulate the immune response by targeting and lysing DCs [154,155]. 
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1.3 INFECTIOUS DISEASES 
A number of major discoveries have helped us in our battle with infectious disease, ranging 
from improved hygiene [156], a better understanding of how microorganisms can spread 
[157], and vaccinations [158]. However, despite these advances, infectious diseases affect 
billions of people. Since 1990 over 400 million disability-adjusted life years (sum of years of 
healthy life lost) attributably to communicable diseases have been saved [159] (Fig. 7). With 
future improvements in our understanding about infectious agents, and how our immune 
system reacts to them we should be able to develop more effective vaccines and treatment that 
could further lower the global impact of infectious diseases. 
Figure 7: Causes of disability-adjusted life years; from www.healthdata.org [159] 
 
Hepatitis in general is inflammation of the liver that can have a number of causes including 
alcohol, fatty liver, drug toxicity, autoimmunity, or the predominant cause of viral infection. 
Infections with the hepatitis viruses are major risk factors for fibrosis and cirrhosis, and HCC 
[22,160,161]. Hepatitis B, C, and δ viruses are transmitted via infected bodily fluids 
parenterally, usually through shared needles of intravenous drug users (IDUs), perinatally, or 
during sexual intercourse [162]. Routes of infection vary in different settings and in different 
parts of the world. Each virus is very different but linked in that they infected hepatocytes. 
HIV-1 and HIV-2 are the causative agents of acquired immunodeficiency syndrome (AIDS), 
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with the HIV-1 pandemic resulting in 1.5 million deaths per year [162]. As with HBV, HCV, 
and HDV, HIV-1 and HIV-2 infect new hosts via infected bodily fluids [162]. 
1.3.1 Hepatitis B Virus 
1.3.1.1 HBV & Disease 
HBV is highly infectious, with over 2 billion people infected at some point [162]. The ability 
to clear the virus without medical intervention depends upon when you are infected. 90% of 
infected adults are able to clear the virus without intervention [162], and adult infection is 
often acquired by sexual transmission or use of contaminated needles. However, 90% of 
perinatal infections will result in chronic hepatitis B (CHB) [162]. 
HBV has a double stranded DNA genome that contains four overlapping reading frames, 
which code for seven proteins [163,164]. Amongst these are three envelope proteins that help 
bind the virus to hepatocytes for infection [165]. Once endocytosed within the hepatocyte 
HBV still has to gain access to the cell nucleus to replicate, which it achieves through use of a 
nuclear localization signal found in its core protein [166]. Once in the nucleus the virus can 
begin transcription of its genome and replication by converting from a relaxed circular DNA 
structure to covalently closed circular (ccc) DNA [163,167]. 
The cccDNA structure is very stable facilitating viral persistence [168], meaning that unless 
the infection is cured it has to be suppressed indefinitely. Current attempts to cure HBV 
infection still rely upon pegylated IFN-α [169], but drugs targeting the HBV reverse 
transcriptase are in development [170]. If a curative treatment is unsuccessful, patients often 
require lifelong drug treatment with Tenofovir to suppress the virus [171]. 
It has been suggested that the size of the inoculum contributes to the outcome of the infection 
[172]. A large inoculation may be cleared eventually, a moderate inoculum may result in 
rapid clearance, while a small inoculum may lead to a large spread and persistent infection. 
This model suggests that a small HBV inoculum that does not break the livers immune 
tolerance will persist, while larger inoculums that break this tolerance will eventually be 
cleared. While HBV infection is mainly considered to be non-cytopathic [163,173], there are 
some arguments against this notion [174]. It is likely that non-antigen specific T cells 
contribute to liver damage via the Fas/Fas-ligand pathway [175], and NK cells via TRAIL 
[176,177]. 
1.3.1.2 HBV Immunology 
Despite the intrinsic ability of the HBV core protein to activate the immune system [178,179], 
the early stages of infection are characterized by an induction of IL-10 production, rather 
than type I IFN, resulting in attenuated responses of NK and T cells [180,181]. This lack of a 
pro-inflammatory response may be due to HBV altering TLR3 signalling and subsequent 
IFN-α production [48,182]. Along with the already tolerogenic nature of the liver, the 
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immune system thus requires a large insult to activate multifunctional virus-specific CD8+ T 
cells that are crucial for viral clearance [177,183]. 
IFN-α stimulation of NK cells is useful during initial stages of infection due to their 
production of IFN-γ and TNF. It has recently been shown that T cell derived IFN-γ and TNF 
are able to induce the decay of the HBV cccDNA [184]. Hence it may be possible that early 
induction of these pro-inflammatory cytokines by NK cells could halt persistent infection. 
Certainly they help provoke an anti-viral environment, and lyse infected cells if NK cells can 
overcome the inhibitory MHC signals [185]. However, if overactive then NK cells may have 
off-target effects and kill uninfected hepatocytes [173,176]. If IFN-α is inadequately produced, 
in combination with IL-10 up-regulation, then NK cells may kill pDCs, and CD8+ T cells 
allowing for further viral spread [163]. 
TRAIL expression of NK cells is seen to be up-regulated in CHB patients [176], and is 
thought to play a role in killing hepatocytes [186] and anti-viral CD8 T cells [187] during 
hepatitis infections. Despite their increased expression of TRAIL, these NK cells have a 
reduced capacity to produce IFN-γ potentially caused by increased levels of IL-10 [188]. 
Although the NK cells have increased TRAIL expression the HBV core protein is able to 
reduce expression of the TRAIL ligand DR5 (TRAIL-R2) on hepatocytes [189], thus reducing 
the potential for virally infected cells to be targeted.  
1.3.2 Hepatitis δ Virus 
1.3.2.1 HDV & Disease 
First identified by Rizzetto et al in 1977 [190,191], HDV was named thus due to the extra 
(delta) antigen involved in HBV infection. An estimated 20 million people are infected with 
HDV [162], which is considered the most severe form of viral hepatitis, as progression to 
cirrhosis is faster, and the risk of HCC greater [192]. 
HDV has since been discovered to be a sub-viral virion, the only one known to infect humans 
[193]. Other known viroids infect plants, which has led to some debate as to the origin of 
HDV [194]. Viable reproduction only occurs in a cell already infected with a hepadnavirus, 
most commonly HBV, and can occur as a simultaneous co-infection or subsequent super-
infection [195]. The HDV consists of a HBV envelope and contains a single strand of circular 
RNA [196] that codes for one protein, the delta protein. 
HDV is likely to use the same viral entry mechanisms as HBV due to the HBV envelope 
proteins, however replication is separate [197], and well reviewed by Taylor 2015 [198]. The 
HDV RNA translocates to the cell nucleus were the genetic material is copied in a double 
rolling-circle replication system reliant on host cell replication factors [197,198]. This results 
in production of HDV mRNA, leading to the production of delta protein, and genomic HDV 
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RNA. Delta protein and HDV RNA are combined in HDV ribonucleoprotein, which is 
packaged in HBV envelope proteins in the Golgi, prior to secretion.  
Due to the use of HBV envelope, the same pathways of infected bodily fluids spread HDV. 
Similarly infection can be effectively vaccinated against using the HBV vaccine. Treatment is 
still restricted to pegylated IFN-α therapy [94,199] which has a 25% response rate [200]. 
However, trials such as the HIDIT studies [201] are aimed at further developing the therapy. 
1.3.2.2 HDV Immunology 
A relatively rare viral hepatitis infection, the immunology of HDV infection is little studied. It 
must also be kept in mind that HDV infection occurs within the context of active HBV 
infection. HDV is also considered to be non-cytopathic, hence it is thought that the immune 
system causes the majority of the disease pathogenesis [202]. 
We know that HDV is capable of inhibiting IFN-α signalling [203], adding to the tolerogenic 
environment created by HBV. In chronic hepatitis δ (CHD) the virus-specific T cell responses 
are weak [202], and prior to our work there were very few investigations of NK cells during 
HDV infection [204,205]. These studies identified NK activity in response to IFN-α therapy 
as important in HDV clearance. 
1.3.3 Hepatitis C Virus 
1.3.3.1 HCV & Disease 
HCV, like the other two hepatitis viruses described, is blood borne and infects roughly 130-
150 million people globally [205]. Of those infected about 30% are able to clear the infection 
spontaneously within six months and will not progress to chronic hepatitis C (CHC), and the 
majority are asymptomatic. Effects of HCV infection were first observed in the 1970s due to 
transfusion patients contracting hepatitis. After the development of assays to detect hepatitis 
A virus (HAV), and HBV, it was determined that a new agent, originally termed non-A non-
B hepatitis, was the cause [206]. 
HCV has since been discovered to be a positive-sense single-stranded RNA virus in the family 
of Flaviviridae. Viral endocytosis into hepatocytes is mediated by clathrin along with a host of 
co-receptors [207,208], including CD81 binding the HCV E2 protein [209]. Once in the cell 
the endosomal pH triggers release of the viral RNA into the cytoplasm, the host machinery 
can then translate the genome; viral proteases then proceed to cut the polyprotein into 10 
viral proteins [210]. 
The history of HCV and IFN therapy have recently been well reviewed by Pawlotsky et al 
2015 [211], and Heim 2013 [91], detailing the history of the use of IFN-α as a therapy and the 
dawn of the new direct acting antiviral (DAA) drugs [212]. IFN-α therapy is believed to work 
by activating the immune system mechanisms acting to eradicate viral infection. However, 
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the use of IFN-α as a therapy alone has poor treatment response rates that have been 
increased with the addition of ribavirin to the treatment regimen, and the pegylation of IFN-α 
[91]. The new DAAs are in effect a game changer in HCV therapy. A slew of studies can be 
summed up by saying effectiveness now ranges from 90-99% [213-215], depending on HCV 
genotype [216].  
The appearance of CD56neg NK cells has been observed during HCV infection and appears to 
be indicative of IFN-α treatment response [115], as does the patients’ IL-28b genotype [217]. 
A very good predictor of response to IFN-α therapy was shown to be the activity of the ISGs 
in the liver of patients, with low ISG activity predicting good response [218,219]. This heavily 
implies that IFN-α therapy works by initiating an immune response that is not occurring, 
possibly due to a lack of danger signals or blockage by viral proteins [220]. 
1.3.3.2 HCV Immunology 
IFN-α is known to be critical during HCV infection [220], however the HCV has a number of 
immune evasion mechanisms. Viral protein E2 can halt pDC IFN-α production [221,222], 
while NS3 inhibits TLR3 signalling [223]. HCV is also non-cytopathic, hence liver damage 
probably originates from the immune responses’ attempts to control and eradicate the 
infection. Again this damage comes from the action of the cytotoxic lymphocyte subsets CD8+ 
T cells and NK cells [224]. While these responses are needed to clear the infection, they are 
required to be specific responses and therefore the off target effects need to be limited [225]. 
NK cells play a crucial role in HCV infection [226]. Particularly the inhibitory KIR2DL3 on 
NK cells and its cognate ligand human leukocyte antigen (HLA)-C1 are reportedly involved 
in clearance of HCV [227], as is IFN-γ production [228]. These studies highlight NK cells as a 
significant effector cell in this context. However, HCV infection can cause NK cells to down 
regulate the activating receptor NKp30 [229], while NKp46 expressing NK cells appear 
ineffective against infection [230]. 
1.3.4 Human Immunodeficiency Viruses 
1.3.4.1 HIV & AIDS 
AIDS is a disease caused by infection with either HIV-1 or HIV-2, and characterized by the 
progressive destruction of immune cells. This destruction, particularly of the CD4 T cells, 
leaves patients susceptible to many opportunistic infections that are generally well controlled 
in healthy individuals such as T. gondii, cryptococcus, P. jirovecii, or cytomegalovirus. There 
is also an increased incidence of some cancers like Karposi’s sarcoma. Thus in the end it is not 
HIV that directly kills the host, rather the host succumbs to other ailments. 
Clinically, Gottlieb first described AIDS in 1981 [231], due to its appearance and apparent 
restriction to the homosexual population in San Francisco and Los Angeles. However, AIDS 
had long been observed in Africa [232,233] and was referred to as ‘slim disease’ due to the 
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wasting effects of the disease. The causative agent, HIV, was initially isolated in 1983 [234], by 
this stage it was known that the disease could be spread sexually, perinatally and through 
contaminated blood products. 
HIV can infect many different immune cells including T cells, dendritic cells, and 
macrophages due to their expression of the CD4 receptor [235] and co-receptor CCR5 or 
CXCR4 [236]. Once in the cell cytoplasm, the viral RNA genome can begin to be transcribed 
by reverse transcriptase into DNA. This viral DNA is then transported to the nucleus and 
integrated into the host genome, where it may lie dormant or begin to replicate [237,238]. 
HIV-1 and HIV-2 viral genomes have approximately 60% sequence homology [239] and 
differ in a number of ways. HIV-2 appears to be less transmissible [240], and fewer of those 
infected progress to AIDS [241]. For these reasons infection with HIV-2 is seen by some to 
act as an attenuated form of HIV, while HIV-1 is responsible for the AIDS pandemic. 
Treatment of HIV infection has progressed rapidly over the last few decades, as AIDS became 
a major global problem and received dedicated research funding. Antiretroviral therapy 
(ART) has helped transform treatment and vastly increased the life span of people infected 
with the virus, saving countless lives and reducing the burden of disease [242]. Currently 
treatment with ART is suggested to start upon diagnosis of the disease irrespective of a 
patients CD4 T cell count [243]. Although we have effective treatment we still lack a 
practicable cure [244], with stem cell transplantation not a viable option for large-scale 
implementation [245]. An effective vaccine is also still a distant goal. There are other effective 
methods to help stop the spread of the disease, with condoms and pre-exposure prophylaxis 
(PrEP) [246] able to significantly reduce infection from sexual encounters.  
1.3.4.2 HIV Infection & Immunity 
HIV entry through a mucosal surface will be encountered by DCs, which will take up the 
virus to present it to CD4 T cells. At the same time a local immune response to the infection 
can begin. However, DCs can pass the virus onto CD4 T cells via the receptor DC-SIGN and 
other surface lectins [247,248]. Once an infected DC arrives in a lymph node, the infection 
can spread systemically [249,250]. If HIV enters intravenously then the virus can travel to any 
tissue and immediately begin to infect T cells, and DCs. 
In infected cells, viral RNA and DNA intermediates will stimulate the PRRs leading to a 
cytokine storm of pro-inflammatory cytokines during acute infection [251,252] (Fig. 8), 
including a substantial and rapid increase in IFN-α. After infection HIV has a number of 
mechanisms to evade immune recognition controlled by accessory proteins, which differ 
between HIV-1 and HIV-2. These proteins are not directly necessary for replication but do 
target host immune proteins thereby enabling effective and efficient transmission and 
replication [253]. The accessory HIV-1 protein Vpu, is known to interrupt the cycling of 
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MHC-like molecules [66] and IRF3 [254], while the HIV-2 Vpx protein can inhibit IRF5 
[255]. 
Declining CD4 T cells, which typifies AIDS progression, occurs either due to activation-
induced cell death, killing by anti-viral cytotoxic cells, or a form of virally induced 
programmed cell death: pyroptosis. CD8 T cells are able to recognize and kill infected cells 
[256,257] but also lyse uninfected CD4 T cells [258], while NK cells are also capable of killing 
infected cells [259]. Recently it has been suggested that pyroptoptic cell death drives CD4 T 
cell depletion [260], which occurs when HIV genetic material is detected in the cytoplasm of 
naïve CD4 T cells [261]. 
Figure 8: Cytokine storm in acute HIV infection [252] 
Innate immunity, involving iNKT and NK cells, also plays an important role in pathogenesis 
[254]. During HIV-1 infection there is a significant reduction of CD4+ iNKT cells [262], with 
the remaining iNKT cells exhibiting functional impairment with reduced IFN-γ production, 
and increased PD-1 expression suggesting exhaustion [263]. Loss of iNKT cell regulation of 
the immune response during HIV-1 infection may hinder effective NK cell and DC function 
[264]. 
NK cells are activated during viremic HIV-1 infection [265], and such activation has been 
associated with disease progression [266]. However, lysis of infected targets may require pDC 
derived IFN-α [267], and the activating receptors NKp46 and NKG2D [268]. During HIV-1 
infection there is a vast increase in the CD56neg NK cells, particularly in viremic patients [116]. 
The origin of these cells in HIV-1 infection has been suggested to be the CD56dim NK cells 
[269]. Regrettably the role of NK cells during HIV-2 infection has not been well studied. The 
one study previously performed identified the viral load during HIV-2 infection to be 
associated with NK cell function [270]. 
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1.4 CHRONIC VIRAL INFECTION 
There appears to be a window in which the cellular immune response can eradicate a viral 
infection. At this juncture NK cells switch their intracellular signalling pathways in response 
to IFN-α stimulation [271], and T cells will start to be killed by NK cells [272]. Thus if a virus 
can persist during this initial period, either due to an underactive immune response or 
unmanageable viral burden, the infection may become chronic. Despite failing to clear 
various infections some persistent infections are kept in check by the immune system and 
remain asymptomatic. In some chronic cytomegalovirus infections there is an expansion of 
NKG2C+, self-KIR+ NK cells [273], which may be involved in keeping the virus in check. 
Following failure to clear a viral infection the immune system may persist in its responses, 
with increased pro-inflammatory, and anti-inflammatory signals. With both these competing 
signals increased, the immune system can become dysfunctional and exhausted. Hence in 
predominantly non-cytopathic infections such as hepatitis, off target activation can cause 
severe damage to the liver [274], while in HIV you find over-activated and functionally 
impaired NK cells. Of course in both hepatitis and HIV infections the virus can cause degrees 
of cell death, the amount of which may well help determine how long it will take to progress 
to cirrhosis or AIDS. 
1.4.1 Chronic Immune Activation 
A big part of the pathology of chronic viral infection is the associated immune activation. 
During HIV-1 infection this chronic activation can have a number of causes, including 
pyroptotic cell death and microbial translocation [275]. This activation causes aging of the 
immune system [276] and also causes co-morbidities such as liver steatosis and 
cardiovascular disease [275,277]. Levels of pro-inflammatory cytokines are increased [252], 
and T cells have been observed to have a persistently activated and exhausted phenotype 
[275]. Additionally, NK cells are continually activated and are likely to contribute to the pro-
inflammatory cytokine milieu with IFN-γ [278]. Even during ART NK cells display a partly 
activated phenotype [279]. 
Chronic immune activation in the liver can eventually lead to severe cirrhosis. Numerous 
studies have linked the rising levels of pro-inflammatory cytokines to worsening stages of 
liver disease [280,281]. The recent Icona Foundation study showed that high levels of TNF 
correlated with an increased risk in advancing to cirrhosis [282], and increased sCD163, 
signifying macrophage activation, is associated with the fibrosis stage [283]. During chronic 
hepatitis activated NK cells are able to alleviate fibrosis by killing non-virus-specific CD8 T 
cells and hepatic stellate cells via TRAIL. Despite this protective action however, NK cells will 
also continue to produce IFN-γ and kill hepatocytes [22]. It has not been fully elucidated if 
the new DAA therapy for HCV is able to alleviate the immune activation. 
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1.4.2 Microbial Translocation 
A major contributor to chronic immune activation is microbial translocation from the gut. 
Immune activation in the gut, with involvement of TNF and IFN-γ, can result in aberrant 
enterocyte turnover and destruction of tight junctions [284]. With the loss of structural 
integrity the gut epithelium becomes more permeable permitting the movement of relatively 
large quantities of bacterial material into the tissues, which can then drain to the liver via the 
portal vein.  
Microbial translocation can be measured as presence of lipopolysaccharide (LPS) levels in the 
general circulation, while the effects can be observed in the increased levels of soluble CD14 
(sCD14) in the blood [281]. CD14 is a co-receptor for LPS, alongside TLR4, found on the 
surface of macrophages that can stimulate activation. Upon activation, membrane bound 
CD14 will be shed as sCD14, and sCD14 can also be secreted. Hepatocytes are reported to 
express and secrete CD14 in response to pro-inflammatory signals [285], suggesting that 
microbial translocation can induce sCD14 from both macrophages (possibly Kupffer cells as 
well), and hepatocytes. Conceivably there are also other routes leading to sCD14 release as 
patients with non-alcoholic steatohepatitis (NASH) [286], and common variable immune 
deficiency (CVID) [287] have increased sCD14 plasma levels. A high level of sCD14 in the 
blood has been reported to be a negative predictor of IFN-α treatment of HCV in HIV/HCV 
co-infection [288]. 
In both HIV-1 and HIV-2 infections the level of microbial translocation, as measured by LPS 
[289], is indicative of CD4 count and viral load [290]. Likewise in hepatitis infections, the 
level of LPS, and by extension microbial translocation, correlates with disease severity in HBV 
and HCV [281]. In both HIV and hepatitis infections, immune activation and microbial 
translocation cause and perpetuate each other, increasing disease severity (Fig 9). 
Understanding and breaking this vicious cycle could lead to effective new treatments [291].  
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 Figure 9: interplay of immune activation and microbial translocation 
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2 AIMS 
As is to be expected from basic science research the precise aims of my work have fluctuated 
over the years depending upon results and collaboration opportunities. However, the over-
arching theme has remained true – improve our understanding of the role of NK cells in viral 
infections. To this end the work included in this thesis explores how the phenotype and 
function of NK cells differ between stages of hepatitis infection and between the virus 
infections themselves. Furthermore, I have investigated if the activation level of NK and iNKT 
cells differs between HIV infections. In addition we asked the question of what effect IFN-α 
therapy of hepatitis has upon innate immune systems, studying the role of sCD14 as a 
biomarker in HCV therapy and the alterations of NK cells in HDV therapy. 
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3 RESULTS AND DISCUSSION 
Paper I: “Compromised Function of Natural Killer Cells in Acute and Chronic Viral 
Hepatitis”. 
Paper II: “Effects of HDV infection and pegylated interferon α treatment on the natural killer 
cell compartment in chronically infected individuals”. 
Paper III: “The Dynamic Relationship between Innate Immune Biomarkers and Interferon-
Based Treatment Effects and Outcome in Hepatitis C Virus Infection Is Altered by 
Telaprevir”. 
Paper IV: “Elevated levels of iNKT cell and NK cell activation correlate with disease 
progression in HIV-1 and HIV-2 infections”. 
3.1 ALTERATIONS OF NK CELLS DURING VIRAL INFECTIONS 
Papers I and IV principally concern the alterations and activation of NK cells that occur in 
viral infections. During viral hepatitis infections major changes in NK cell phenotype and 
function occur progressively throughout acute and chronic infections. These alterations are 
shared between infections regardless of the infecting virus. Along the same lines as this, we 
observed no principle difference in NK cell activation levels between HIV-1 and HIV-2 
infections, with changes in activation more associated with disease progression and closely 
linked to viral loads. 
3.1.1 NK Cells During Acute & Chronic Hepatitis Infections 
In Paper I, utilising material collected by our collaborators at Hannover Medical School, we 
were able to perform a comprehensive examination of NK cells during both acute and 
chronic phases of HBV and HCV infection, and chronic phase of HDV infection. The first 
thing to notice is a substantial increase in the percentage of CD56bright NK cells during the 
acute infections relative to both healthy individuals and the chronic phases. Levels of CD56dim 
NK cells were only increased in chronic HCV and HDV infections, not HBV infection. 
Decreases in expression of several NK cell surface markers during infection did not appear to 
be specific to either NK cell subset. We did however see differences between the acute and 
chronic phases, with reductions of CD25 and DNAM-1 on CD56dim NK cells in chronic 
hepatitis, while reduction of CD48 on CD56bright NK cells was again associated with chronic 
infection. Despite these changes in subset distribution and receptor expression between the 
acute and chronic phases, there were minimal alterations of maturation-associated makers 
(i.e. CD57, KIRs, and NKG2A) on CD56dim NK cells.  
Induction of in vitro functional responses, following stimulation with K562 target cells with 
addition of IFN-α, were generally reduced in NK cells from hepatitis patients compared to 
controls. NK cells did however retain a multifunctional profile (Fig. 10). One noticeable 
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difference between acute and chronic HBV infection is that NK cells in the former condition 
produced less macrophage inflammatory protein (MIP)-1β, an effect not seen for HCV 
infection. 
Figure 10: NK cell multi-functional responses to K562 +/- IFN-α during different phases of 
hepatitis infections (Paper I) 
We performed a principle component analysis (PCA) of the NK cell profile to assess which 
combination of NK cell markers were significantly different between the viral infections and 
disease stages. Our PCA indicated relatively little difference in phenotype and function of NK 
cells between the viral infections; rather it was between the acute and chronic infections that 
we found the major alterations of the NK cells. Highly significant changes in the NK cells 
were a shift in subset distribution towards CD56bright NK cells, %NKG2A+ NK cells, and 
TRAIL expression on all NK cells. Expression levels of NKG2A are likely to be related to the 
increased size of the CD56bright subset (Fig. 11). Although our study did not consider CD56neg 
NK cells and how their appearance may affect NK cell subset distribution, as our results were 
based upon NK levels as a percent of lymphocytes this guards against the loss of CD56dim NK 
cells appearing as an increase in CD56brights NK cells. 
Regrettably in Paper I we did not explore alterations of the activating NCRs NKp30, NKp44, 
and NKp46, or NKG2C on NK cells. In 2011, Alter et al [292] showed that HCV infections 
were associated with a decrease in NKp30, and NKp46 expression on NK cells, although 
distribution of these markers between CD56dim and CD56bright NK cell subsets or expression 
levels were not explored. The role of NKp46 in CHC in particular is perplexing with reports 
indicating that it may be involved in suppressing HCV replication [293] but that NKp46+ NK 
cells are pathologically activated and irresponsive to therapy [230]. Additionally in HBV 
infection Zaho et al [294] reported increases of NCR expression on NK cells, particularly 
during the acute phase. 
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Figure 11: PCA of NK cell parameters between acute and chronic hepatitis infections (Paper I) 
In 2009, Oliviero et al [295] examined expression levels of the NCRs and NKG2C of NK cells 
during CHB and CHC infections. They described that NKG2C was significantly increased on 
NK cells from CHB but not CHC infection, while levels of NCR expression were unchanged 
on NK cells that expressed NCRs. Interestingly their functional assays indicated that NK cells 
from patients with CHC had greater degranulation responses to P815 target cells with 
cytokine stimulation, as compared to patients with CHB infection or healthy controls. 
However when switching to K562 cell targets NK cells from CHC subjects had the same 
CD107a response as healthy controls, while NK cells from CHB had a lower degranulation 
response than both. When using anti-NCR stimulation and again P815 targets they saw an 
increase in the CD107a response from NK cells from CHC infected patients. These 
digressions from our results intonates that the target cell line and cytokine mix used for 
functional assays may lead to differing results, although differences between patient cohorts 
are hard to exclude. Furthermore, the differing receptor expression on NK cells from the 
various viral infections may also have a bearing on the functional responses, and be a key 
factor affecting disease outcome.  
In our study, pan-KIR expression was not altered due to infection, nor did it differ between 
the infections. Oliviero et al [295] observed a slight decrease in inhibitory KIR expression in 
CHC compared to CHB and controls, while similar to us Alter et al [292] saw no difference in 
NK cell KIR expression between acute or chronic HCV compared to controls. However, in a 
more detailed examination of the KIR profile Oliviero et al observed that the reduction was 
due to reduced KIR3DL1, and a trend for reduced KIR2DL1 [295], similar to our unpublished 
results currently being compiled for publication.  
3.1.2 NK Cell Activation During HIV Infections 
For Paper IV, as part of a wider collaboration of HIV-2 studies in a prospective cohort in 
Guinea-Bissau, we were able to demonstrate that activation levels exhibited by NK cells is 
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associated more with disease activity and progression, rather than with the specific type of 
HIV infection. Additionally by comparing viremic versus non-viremic HIV-2 infections we 
were able to delineate if altered activation levels of the NK cells was due to infection or disease 
progression. 
Similar to prior studies of HIV-1 infection [296], we observed a trend for fewer CD56dim NK 
cells in the blood and a significant reduction in the number of CD56bright NK cells. Looking 
within the HIV-2 infected group we observed that the reduction of CD56dim NK cells occurred 
in viremia, while the reduced numbers of CD56bright NK cells appeared to be related to 
infection as it also occured in non-viremic persons. In 2004 Alter et al suggested that NK cell 
numbers in HIV-1 infections were related to viremia [265], implying that in both HIV-1 and 
HIV-2 infections depletion of NK cells is associated with viremia. 
Our study utilized the expression of CD38 as a marker for cellular activation [297]. HIV-1 
infection was associated with greater CD56dim NK cell activation when compared to 
community-matched healthy controls and HIV-2 infected persons. Along with studies on 
HIV-1 [265,266,298], our HIV-2 viremia results indicate this increase in activation is driven 
by viral replication. CD56bright NK cells have a higher activation level in all settings of HIV 
infection compared to non-infected controls, with HIV-1 infection exhibiting greater 
activation than HIV-2 infection. Viremia in HIV-2 infection associates with increased 
activation of the CD56bright NK cells, but even the non-viremic HIV-2 infected persons have 
higher activation than the controls indicating that both infection status and viral replication 
are involved in the generation of activated of CD56bright NK cells (Fig. 12).  
Similar to previous studies [262], CD4+ iNKT cell numbers were reduced in HIV-1 infections 
relative to controls, and in HIV-2 infections the reduction of cell numbers was related to 
viremia. Also paralleling prior studies [263], the activation status of iNKT cells in all HIV 
infections was increased and correlated with increasing viral loads and declining CD4 T cells. 
The activation levels of iNKT and NK cells in our study were very closely correlated, 
particularly CD4+ iNKT cells and CD56bright NK cells. Additionally, iNKT and NK cell 
activation was concurrent with CD4 T cell activation (Fig. 13), implying that the same 
mechanisms may be causing activation of these cell types. 
Due to the limited sample availability, our analysis of NK cell populations was 
disappointingly limited, and we could not perform a more extensive phenotypic or functional 
assessment in the different infections. In particular it would be fascinating to examine NCR 
expression of NK cells in HIV-2 relative to HIV-1 [299], and relate this information to their 
functional capabilities. Despite these gaps in the literature, the findings in Paper IV along 
with other HIV studies [266,270,300] indicate that activation of NK cells during HIV 
infection is concomitant with other immune activation events (Fig. 13). It is likely that this 
apparent increase in NK cell activation and limited functional capacity [270,298] reflects 
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chronic immune activation, which may also be the underlying cause of the increase in 
CD56neg NK cells. 
 
 
Figure 12: Activation levels of NK cell subsets in A) HIV infections, and B) HIV-2 non-viremic 
(aviremic) vs viremic infections; *Significance (Paper IV) 
 
 
 
 
 
Figure 13: Concomitant cellular activation during HIV infection (Paper IV) 
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3.1.3 NK Cells in Chronic Viral Infections 
Throughout these studies it has been difficult to ascertain which alterations of the NK cells 
represents a response to chronic infection, and which are resultant from general broad-based 
chronic inflammation. A further caveat of our studies is that we have access only to blood 
samples, and thus can only surmise on how organ-resident NK cells are altered. This will pose 
a problem if they respond or are affected differently in tissues such as the liver [301]. 
Proportions of NK cells within peripheral blood appear to differ between hepatitis and HIV 
infections with levels of NK cells increasing in hepatitis and decreasing in HIV. Comparative 
studies of HIV and HCV have shown that NK cells decline in both infections at the expense 
of CD56dim cells [296], most likely due to a transition of CD56dim to CD56neg NK cells [269], a 
subset we did not measure. As we observe that the levels of CD56bright NK cells are affected in 
HIV infected patients, and levels of CD56dim NK cells are associated with markers of disease 
progression, we could surmise that differences in NK cell levels between these infections are 
due to differing levels of chronic inflammation. Regrettably we were unable to stratify our 
chronic hepatitis patients by fibrosis stage to examine if this affected NK cell subset 
distribution. We do know that chronic inflammation is linked to more severe fibrosis in viral 
hepatitis and disease progression in HIV infections, thus it would be interesting to assess 
distribution of NK cell subsets along with inflammatory status between these infections and 
non-viral inflammatory conditions such as NASH. In this way we could attempt to reconcile 
our results with others showing declining NK cell numbers in both HIV and HCV [296]. 
Having only measured CD38 in our HIV study, we are unable to comprehensively compare 
the NK cell phenotype between the HIV infections. As NK cells from HIV-1 long-term non-
progressors do not appear to differ from viremic HIV-1 persons [298], we could hypothesise 
that the less likely to progress HIV-2 infection also does not cause major phenotypic changes 
in NK cells. Certainly NCR expression would be fascinating to assess due to the role of these 
receptors in mediating and regulating NK cell function in HIV infection [299] as well as viral 
hepatitis [295]. 
During both HIV and hepatitis infection there is an increased activation of the NK cells 
accompanied with a reduced functional capacity. Thus it appears that in chronic infection NK 
cells may be less responsive to the chronic inflammatory conditions in which they reside. It 
would be intriguing to further explore the functional differences of NK cells between chronic 
infections, while controlling for levels of inflammation. 
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3.2 EFFECTS OF IFN-α IN HEPATITIS THERAPY 
Pegylated IFN-α and ribavirin has been the basis for hepatitis treatment for many years, and 
its use afforded us the opportunity to examine the effects of IFN-α upon the immune system. 
Both Papers II and III explore the modulatory effects of IFN-α therapy in chronic hepatitis 
upon innate immunity. Paper II, and its associated work, shows how the NK cell response to 
IFN-α therapy is altered, while Paper III examines sCD14 levels over the course of IFN-α 
therapy, with or without the new DAA drugs. 
3.2.1 Effects of IFN-α Therapy on NK Cells 
In Paper II we studied the effects that IFN-α therapy has upon NK cells during chronic HDV 
infection. In our cohort of HDV patients we observed that, compared to healthy donors, there 
were higher proportions of both CD56dim and CD56bright NK cells in the peripheral blood. 
Following 12 weeks of IFN-α therapy there was a significant decrease in the number of 
CD56dim NK cells; those that were left had a more immature phenotype than at baseline with 
increased NKG2A and less CD57 expression (Fig. 14). Similar to observations in HBV [302] 
and HCV therapy [303,304] the numbers of CD56bright NK cells significantly increase after 12 
weeks of therapy, implicating IFN-α in arresting NK cell maturation. 
 
Figure 14: Number of CD56dim NK cells exhibiting maturation markers in CHD patient before 
(white bars) and after (black bars) 12 week IFN-α therapy; *Significance (Paper II) 
NK cell phenotypes were significantly altered after 12 weeks of IFN-α therapy in our HDV 
cohort. Following therapy, CD56dim NK cells expressed less CD16, NKG2D, and less of the 
inhibitory receptor Siglec-7. While CD56bright NK cells also expressed less CD16, and NKp30, 
their expression of Siglec-7 was increased. The decrease in NKp30 levels was not seen in a 
previous study of IFN-α therapy of HCV [303]; the same study also reports significant 
decreases in Siglec-7 expression on NK cells but failed to clearly distinguish between the 
CD56dim and CD56bright NK cells. However, in another study of HBV and HCV infection, 
Siglec-7 negative NK cells were associated with reduced expression of CD16 and NCRs, and 
suggested to be dysfunctional [305]. 
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IFN-α therapy had profound effects upon the functionality of NK cells. Not only was 
responsiveness to K562 target cells reduced significantly, induction of functions by in vitro 
IFN-α stimulation was also diminished. NK cells, from week 12 samples, displayed limited 
increase in CD107a expression in response to IFN-α, and no increase in production of pro-
inflammatory cytokines (Fig. 15). Induction of TRAIL expression was also stunted in 
response to IFN-α, however as post therapy levels of TRAIL were higher than those observed 
at baseline, the level of TRAIL following IFN-α stimulation was very similar between baseline 
and week 12 samples. 
A possible explanation for the stunted maturation and refractory response to IFN-α is the 
changes in NK cell intracellular signalling caused by therapy. Following IFN-α therapy we 
found significantly increased levels of phosphorylated signal transducer and activator of 
transcription (pSTAT) 1 and pSTAT4 in the NK cells. However, the in vitro potential for 
IFN-α to stimulate the induction of pSTAT4 was severely reduced following therapy (Fig. 16), 
suggesting that IFN-α therapy predisposes NK cells to function primarily through the 
pSTAT1 pathway, which is involved in NK cell maturation and degranulation. This may help 
explain why IFN-α could no longer induce production of pro-inflammatory cytokines, a 
predominantly pSTAT4-dependent pathway, and the stunted maturation. The timing of this 
switch may have some bearing on treatment outcome [306].  
 
 
Figure 15: Functional response of NK cells to K562 +/- IFN-α before and after IFN-α therapy for 
CHD; *Significance (Paper II) 
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Clearly, prolonged therapy with IFN-α has varied effects upon NK cells with CD56dim NK cells 
generally decreasing activating and inhibitory surface receptors, with the exception of 
NKG2A; while the CD56bright population displays both increases and decreases of receptor 
expressions. We also observed, although did not publish, the changes occurring in the 
CD56neg NK cell population during IFN-α therapy. Lower levels of this abnormal NK cell 
subset, prior to IFN-α therapy of HCV, is associated with a better treatment response [307]. 
During IFN-α therapy for HDV these CD56neg NK cells appear to recover their phenotype 
towards that of CD56dim NK cells with restored expression of NKp46, NKG2D, and increased 
TFs EOMES and T-bet (Fig. 17). We were unable to assess if this potential recovery was 
linked to treatment success but this topic is certainly worthy of future study. However, a high 
baseline proportion of CD56dim NK cells was associated with a good treatment response; these 
higher levels of CD56dim NK cells possibly correlate with fewer CD56neg NK cells, a pattern 
which was previously linked to better treatment responses in HIV/HCV co-infections [288].  
 
Figure 16: Reduction of pSTAT4 inducibility in NK with IFN-α following CHD therapy with IFN-
α; *Significance (Paper II) 
3.2.2 Biomarker Alterations During IFN-α Therapy 
For Paper III we were fortunate enough to be able to obtain prospectively collected HCV 
plasma samples from the Karolinska University Hospital bio-bank before and during IFN-α 
therapy. Using these samples we measured the levels of sCD14 and IL-18 for patients 
receiving either, at the time standard, dual therapy of IFN-α and ribavirin, or the new triple 
therapy that had the addition of the DAA protease inhibitor, Telaprevir. 
Patients undergoing therapy with IFN-α experienced significantly increased plasma levels of 
sCD14 relative to pre-treatment levels, but the measurable dynamic range of sCD14 was 
limited. Previously it has been shown that high levels of sCD14 associate with advanced liver 
disease in HBV, and HCV infections [281]. Consonant with this we observed in our dual 
therapy cohort that the lowest baseline levels of sCD14 associated with treatment response; 
this association has also been made in treatment of HIV-1/HCV co-infection [288]. However, 
in our study, this relationship was ablated by the addition of Telaprevir to the treatment 
regimen (Fig. 18). For the triple therapy cohort a different pattern emerged, as a larger 
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increase of sCD14 after 4 weeks of therapy associated with treatment response. This 
observation adds weight to the thought that Telaprevir improves the effectiveness of IFN-α 
therapy by restoring IFN-α sensitivity [91]. 
An on therapy increase of pro-inflammatory cytokine IL-18 was observed in our dual therapy 
cohort; this was not seen in the triple therapy cohort where the patients exhibited elevated 
baseline IL-18 levels. Potentially, these higher IL-18 levels in the triple therapy cohort were 
due to over half the group having stage 4 liver fibrosis. In contrast, we observed an increase of 
IL-18 after 4 weeks of dual therapy that was not seen for triple therapy. Furthermore, the 
lower baseline levels of IL-18 were associated with dual therapy response, but again the effect 
was not observed in triple therapy. Given the high baseline levels of IL-18 in the triple therapy 
cohort, it was difficult to interpret if Telaprevir affects the patient’s IL-18 response to IFN-α 
therapy. 
 
Figure 17: Normalisation of CD56neg NK cell phenotype to that of CD56dim NK cells following IFN-
α therapy for CHD; *Significance (unpublished data) 
3.2.3 Predicting IFN-α Therapy Response 
A number of soluble and cellular markers have previously been suggested to be linked to 
disease progression or help predict response to IFN-α therapy. The presence of CD56neg NK 
cells has been mentioned previously; sCD163 is linked to fibrosis in HBV and HCV infections 
[283,308], as well as being associated with IL-28B (IFN-λ3) genotype [309] which is predictive 
of IFN-α therapy outcome [310]. Education of NK cells through KIR2DL3 is associated with 
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viral clearance [227]. More recently, levels of soluble Siglec-7 and the presence of Siglec-7 
negative NK cells have been correlated with disease severity in hepatitis [305]. Additionally, 
the levels of TRAIL on NK cells induced by therapy was linked to a favourable outcome [311], 
while NKp46+ NK cells were reported to not respond to therapy [230]. The strongest reported 
predictor of IFN-α treatment response for HCV is the hepatic expression of four ISGs [218], 
including ISG15 that has also been linked to treatment response in HBV infection [312]. 
 
Figure 18: Increased sCD14 during A) dual therapy and B) triple therapy. Baseline levels of sCD14 
associated with treatment response in C) dual therapy but D) not triple therapy; 
*Significance (Paper III) 
The two biomarkers that we have reported on here, i.e. high baseline levels of CD56dim NK 
cells and low levels of plasma sCD14, give credence to the idea that IFN-α therapy requires 
the innate immune system to not be in a state of over-activation or exhaustion to be effective. 
With the myriad of innate biomarkers linked to HCV infection resolution and treatment 
response, we can begin to build a picture of the NK cell compartment ideally suited to help 
IFN-α therapy work effectively. However, what appears to be a crucial factor in treatment 
response is the ability of IFN-α to further induce ISG expression in the liver, which may only 
be possible if the system has not been exhausted by systemic chronic immune activation. 
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3.3 NK CELLS IN THE AGE OF DAA 
Fibrosis stage and chronic inflammation are good indicators of how a patient will respond to 
IFN-α therapy. Therefore it is of great interest that in Paper III the effectiveness of triple 
therapy was not confined to patients with the lowest levels of sCD14, and by implication not 
as affected by chronic inflammation. Thus we can speculate whether there is an active role for 
NK cells in the new DAA therapy or if they are superfluous. 
At the time of writing there are two prominent published articles examining NK cells during 
IFN-free DAA therapies for HCV infection. Serti et al [313] reported that the increased levels 
of NKp30, NKp46, and NKG2A returned to healthy control levels after 8 weeks of treatment. 
Functional responses of NK cells also normalised to levels exhibited by healthy controls with 
decreases in K562 degranulation response and TRAIL expression, and increases in IFN-γ 
secretion. A possible underlying cause of these changes may be declining levels of pSTAT1 in 
NK cells during DAA therapy, unlike IFN-α therapy. 
Recent results by Spaan et al [314] confirm the decreased expression of NKp30, NKp46, 
NKG2A, and TRAIL on NK cells over the course of therapy. This study also suggested that 
DAA therapy was associated with a decrease of ISG mRNA expressed by leukocytes. 
Regrettably, neither study examined the CD56neg NK cells, but nonetheless these papers 
suggest that DAA therapy restores NK cell phenotype and function to that observed in 
healthy controls. The mechanisms behind this action still require investigation, but a 
reasonable hypothesis would be that DAA in halting viral replication alleviates chronic 
inflammation and unburdens the NK cells, allowing them to function normally and 
potentially aid viral clearance. 
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4 CONCLUDING REMARKS 
This thesis aimed to explore how NK cells and innate immune activation change during viral 
infections, and what effect IFN-α therapy had upon them. The data and conclusions from the 
papers presented show that NK cell distribution and activity are important during chronic 
viral infection, and that IFN-α as a therapy fundamentally alters these aspects of NK cell 
biology. Furthermore, broad-based persistent activation of the innate immune system occurs 
during chronic viral infection, and during IFN-α therapy. The main conclusion from each 
paper is as follows: 
• Alterations of NK cell phenotype and functional capabilities in viral hepatitis 
infections are dependent upon disease stage (Paper I) 
• IFN-α therapy of CHD results in refractory NK cell responses to IFN-α, along with a 
propensity to signal through pSTAT1 rather than pSTAT4 (Paper II) 
• Baseline levels of sCD14 are predictive of IFN-α treatment of CHC, an effect ablated 
by DAAs (Paper III) 
• Activation levels of NK, iNKT, and CD4 T cells increase concomiantly with increased 
HIV replication (Paper IV) 
Together these findings help illustrate the roles that chronic infection and IFN-α therapy have 
in altering NK cells and the wider innate immune system. These conclusions only allude to 
potential mechanisms that require further study. 
4.1 FUTURE DIRECTIONS 
Despite my conjecture CD56neg NK cells still hold many mysteries. The precise origin of these 
cells in chronic infections, and if they do have a function, remains to be ascertained. However 
a suitable phenotypic characterization of these cells in healthy individuals must be initially 
completed to allow for comparative studies to be performed. 
Precise effects of chronic inflammation upon NK cells still remain to be separated from those 
caused by chronic infection. Therefore studies comparing NK cells from different hepatitis 
fibrosis stages and NASH could be performed to provide answers in this area. To 
complement such studies it could be useful to further examine the effects of DAA therapy 
upon NK cells. As we see a normalization of NK cell phenotype and function in IFN-free 
therapy it would be of interest to examine which intracellular mechanisms are affected during 
these new DAA therapies. Particularly parameters such as pSTAT levels and inducibility, 
along with potential epigenetic changes would shed light on how this effective therapy affects 
the immune system. 
 

  37 
5 ACKNOWLEDGEMENTS 
Moving to Sweden for my PhD has definitely been one of my better decisions. From the 
outset I’ve have the chance to work with some fantastically talented and friendly people who 
have helped get me to this stage, and without whom this thesis would not have happened. 
Johan Sandberg my main supervisor. I can’t thank you enough for taking me on as a student. 
Your experience in everything scientific has been invaluable, along with your patience in 
allowing me the time and space to mature. I couldn’t have asked for a better supervisor. 
My co-supervisors: Hans-Gustaf Ljunggren thanks for replying to my random email and 
inviting me over to KI even if it was Huddinge, and your continued support. Niklas 
Björkström I am indebted to you for all of your advice and discussions over the years that 
certainly got me thinking. Karolin Falconer, thank you for your help and taking care of the 
clinical side of my projects. 
My mentor Kerry Lavender, who taught me the way of NK cells, suggested I apply to the 
Karolinska, and continuing to be a dear friend. Cheers. 
The German collaborators. Sebastian Lunemann, thank you for all your help from lab work 
to paper writing, you certainly made the start of my PhD relatively easy and without a doubt 
fun. Julia Hengst, always a pleasure when you visit. And Heiner Wedemeyer for your 
enduring enthusiasm for our work. 
Many thanks to Su Bächle for asking for my opinion on NK cells, and letting me in on the 
HIV project with Marianne Jansson. All of the past and present members of the 
Sandberg/Moll Constellation, thank you for enduring my NK cell stuff. 
Former and fellow flow cytometry administrators Sandra, Martin, Monika, and Heinrich; 
thank you for making this duty less laborious. Margit, thank you for taking care of all the 
student administration with a smile. 
For helping me have a life outside the lab thank you Kim, Ginny, Steph & John, Martha, 
Erna, Nikolai, Dom, Marianne, Emma, Sush, Vivien, and Su & Filip. All the other CIMians 
thank you for pretending to know what I was saying. 
“I may not have gone where I intended to go, but I think I have ended up where I needed to be”. 
Thanks to all my family and friends for their continued support in helping me get there. 
 
 38 
6 REFERENCES 
1. Pasteur (1881) On The Germ Theory. Science 2: 420-422. 
2. Metschnikoff E (1891) Lecture on Phagocytosis and Immunity. BMJ 1: 213-217. 
3. Sternberg GM (1895) Explanation Of Acquired Immunity From Infectious Diseases. 
Science 1: 346-349. 
4. Dictionary OE "immunity, n.": Oxford University Press. 
5. Doisne JM, Balmas E, Boulenouar S, Gaynor LM, Kieckbusch J, et al. (2015) Composition, 
Development, and Function of Uterine Innate Lymphoid Cells. J Immunol 195: 3937-
3945. 
6. Rajagopalan S (2014) HLA-G-mediated NK cell senescence promotes vascular remodeling: 
implications for reproduction. Cell Mol Immunol 11: 460-466. 
7. Artis D, Spits H (2015) The biology of innate lymphoid cells. Nature 517: 293-301. 
8. Canton J, Neculai D, Grinstein S (2013) Scavenger receptors in homeostasis and immunity. 
Nat Rev Immunol 13: 621-634. 
9. Odegaard JI, Chawla A (2015) Type 2 responses at the interface between immunity and fat 
metabolism. Curr Opin Immunol 36: 67-72. 
10. Hendricks DW, Min-Oo G, Lanier LL (2015) Sweet is the Memory of Past Troubles: NK 
cells Remember. Curr Top Microbiol Immunol: Epub ahead of print. 
11. Bonnardel J, Da Silva C, Henri S, Tamoutounour S, Chasson L, et al. (2015) Innate and 
Adaptive Immune Functions of Peyer’s Patch Monocyte-Derived Cells. Cell Rep 11: 
770-784. 
12. Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune 
system. Nat Immunol 16: 343-353. 
13. Yarovinsky F (2014) Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol 
14: 109-121. 
14. Shekhar S, Peng Y, Gao X, Joyee AG, Wang S, et al. (2015) NK cells modulate the lung 
dendritic cell‐mediated Th1/Th17 immunity during intracellular bacterial infection. 
Eur J Immunol 45: 2810-2820. 
15. Pahl J, Cerwenka A (2015) Tricking the balance: NK cells in anti-cancer immunity. 
Immunobiology: Epub ahead of print. 
16. Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY (2015) Tissue residency of innate 
lymphoid cells in lymphoid and nonlymphoid organs. Science 350: 981-985. 
17. Hoeffel G, Ginhoux F (2015) Ontogeny of Tissue-Resident Macrophages. Front Immunol 
6:486. 
18. Pichyangkul S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Im-Erbsin R, et al. (2015) 
Tissue Distribution of Memory T and B Cells in Rhesus Monkeys following Influenza 
A Infection. J Immunol 195: 4378-4386. 
19. Sun M, He C, Cong Y, Liu Z (2015) Regulatory immune cells in regulation of intestinal 
inflammatory response to microbiota. Mucosal Immunol 8: 969-978. 
20. Paun A, Danska JS (2015) Immuno-ecology: how the microbiome regulates tolerance and 
autoimmunity. Curr Opin Immunol 37: 34-39. 
21. Szabo G, Petrasek J, Bala S (2012) Innate Immunity and Alcoholic Liver Disease. Digestive 
Diseases 30: 55-60. 
22. Rehermann B (2013) Pathogenesis of chronic viral hepatitis: differential roles of T cells 
and NK cells. Nat Med 19: 859-868. 
23. Kondo M (2010) Lymphoid and myeloid lineage commitment in multipotent 
hematopoietic progenitors. Immunol Rev 238: 37-46. 
24. De Kleer I, Willems F, Lambrecht B, Goriely S (2014) Ontogeny of Myeloid Cells. Front 
Immunol 5: 423. 
  39 
25. Vermijlen D, Prinz I (2014) Ontogeny of Innate T Lymphocytes – Some Innate 
Lymphocytes are More Innate than Others. Front Immunol 5: 486. 
26. Satpathy AT, Wu X, Albring JC, Murphy KM (2012) Re(de)fining the dendritic cell 
lineage. Nat Immunol 13: 1145-1154. 
27. Schraml BU, Reis e Sousa C (2015) Defining dendritic cells. Curr Opin Immunol 32: 13-
20. 
28. Swiecki M, Colonna M (2015) The multifaceted biology of plasmacytoid dendritic cells. 
Nat Rev Immunol 15: 471-485. 
29. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, et al. (2013) Innate lymphoid 
cells--a proposal for uniform nomenclature. Nat Rev Immunol 13: 145-149. 
30. Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, et al. (2014) Human NK cell 
response to pathogens. Semin Immunol 26: 152-160. 
31. Lodoen MB, Lanier LL (2006) Natural killer cells as an initial defense against pathogens. 
Curr Opin Immunol 18: 391-398. 
32. Goulder PJR, Watkins DI (2008) Impact of MHC class I diversity on immune control of 
immunodeficiency virus replication. Nat Rev Immunol 8: 619-630. 
33. Klein L, Kyewski B, Allen PM, Hogquist KA (2014) Positive and negative selection of the 
T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol 14: 377-391. 
34. Billerbeck E, Thimme R (2008) CD8+ regulatory T cells in persistent human viral 
infections. Hum Immunol 69: 771-775. 
35. Roche PA, Furuta K (2015) The ins and outs of MHC class II-mediated antigen processing 
and presentation. Nat Rev Immunol 15: 203-216. 
36. Bedoui S, Greyer M (2014) The role of dendritic cells in immunity against primary Herpes 
Simplex Virus infections. Front Microbiol 5: 533. 
37. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, et al. (2003) Selection of 
evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422: 
164-169. 
38. Kjer-Nielsen L, Patel O, Corbett AJ, Nours J, Meehan B, et al. (2012) MR1 presents 
microbial vitamin B metabolites to MAIT cells. Nature 491: 717-723. 
39. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, et al. (1994) Recognition of 
a lipid antigen by CD1-restricted alpha beta+ T cells. Nature 372: 691-694. 
40. Macho-Fernandez E, Brigl M (2015) The Extended Family of CD1d-Restricted NKT Cells: 
Sifting through a Mixed Bag of TCRs, Antigens, and Functions. Front Immunol 6: 
362. 
41. Siddiqui S, Visvabharathy L, Wang C-R (2015) Role of Group 1 CD1-Restricted T Cells in 
Infectious Disease. Front Immunol 6: 337. 
42. Flajnik MF, Kasahara M (2009) Origin and evolution of the adaptive immune system: 
genetic events and selective pressures. Nat Rev Gen 11: 47-59. 
43. van der Meer J, Joosten L, Riksen N, Netea MG (2015) Trained immunity: A smart way to 
enhance innate immune defence. Mol Immunol 68: 40-44. 
44. Mehta S, Jeffrey KL (2015) Beyond receptors and signaling: epigenetic factors in the 
regulation of innate immunity. Immunol Cell Biol 93: 233-244. 
45. Chow J, Franz KM, Kagan JC (2015) PRRs are watching you: Localization of innate 
sensing and signaling regulators. Virology 479: 104-109. 
46. Trigg BJ, Ferguson BJ (2015) Functions of DNA damage machinery in the innate immune 
response to DNA virus infection. Curr Opin Virol 15: 56-62. 
47. Vénéreau E, Ceriotti C, Bianchi M (2015) DAMPs from Cell Death to New Life. Front 
Immunol 6: 422. 
48. Zhang E, Lu M (2014) Toll-like receptor (TLR)-mediated innate immune responses in the 
control of hepatitis B virus (HBV) infection. Med Microbiol Immunol 204: 11-20. 
 40 
49. Mason CP, Tarr AW (2015) Human lectins and their roles in viral infections. Molecules 
20: 2229-2271. 
50. Lamkanfi M, Kanneganti T-D (2012) Regulation of immune pathways by the NOD-like 
receptor NLRC5. Immunobiology 217: 13-16. 
51. Nan Y, Nan G, Zhang Y-JJ (2014) Interferon induction by RNA viruses and antagonism 
by viral pathogens. Viruses 6: 4999-5027. 
52. Wu B, Hur S (2015) How RIG-I like receptors activate MAVS. Curr Opin Virol 12: 91-98. 
53. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA (2011) Pattern Recognition 
Receptors and the Innate Immune Response to Viral Infection. Viruses 3: 920-940. 
54. Joffre OP, Segura E, Savina A, Amigorena S (2012) Cross-presentation by dendritic cells. 
Nat Rev Immunol 12: 557-569. 
55. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded 
RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738. 
56. Perales‐Linares R, Navas‐Martin S (2013) Toll‐like receptor 3 in viral pathogenesis: friend 
or foe? Immunology 140: 153-167. 
57. Gilliet M, Cao W, Liu Y-JJ (2008) Plasmacytoid dendritic cells: sensing nucleic acids in 
viral infection and autoimmune diseases. Nat Rev Immunol 8: 594-606. 
58. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses 
by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-
1531. 
59. Haglid KG, Haerger A, Hansson HA, Hyden H, Persson L, et al. (1975) Letter: 
Immunohistochemical localisation of S-100 protein in brain. Nature 258: 748-749. 
60. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, et al. (2004) Interferon-α induction 
through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and 
TRAF6. Nat Immunol 5: 1061-1068. 
61. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, et al. (2004) Role of a 
transductional-transcriptional processor complex involving MyD88 and IRF-7 in 
Toll-like receptor signaling. PNAS 101: 15416-15421. 
62. Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex 
web of host defenses. Annu Rev Immunol 32: 513-545. 
63. Norment AM, Salter RD, Parham P, Engelhard VH, Littman DR (1988) Cell-cell adhesion 
mediated by CD8 and MHC class I molecules. Nature 336: 79-81. 
64. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, et al. (1999) RGD 
peptides induce apoptosis by direct caspase-3 activation. Nature 397: 534-539. 
65. van de Weijer ML, Luteijn RD, Wiertz E (2015) Viral immune evasion: Lessons in MHC 
class I antigen presentation. Semin Immunol 27: 125-137. 
66. Sandberg JK, Andersson SK, Bächle SM, Nixon DF, Moll M (2012) HIV-1 Vpu 
Interference with Innate Cell-mediated Immune Mechanisms. Cur HIV Res 10: 327-
333. 
67. Moll M, Andersson SK, Smed-Sorensen A, Sandberg JK (2010) Inhibition of lipid antigen 
presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from 
endosomal compartments. Blood 116: 1876-1884. 
68. Isaacs A, Burke DC (1959) Viral interference and interferon. British medical bulletin 15: 
185-188. 
69. Taylor KE, Mossman KL (2013) Recent advances in understanding viral evasion of type I 
interferon. Immunology 138: 190-197. 
70. Doherty DG (2015) Immunity, tolerance and autoimmunity in the liver: A comprehensive 
review. J Autoimmun: Epub ahead of print. 
71. Tiegs G, Lohse AW (2010) Immune tolerance: What is unique about the liver. J 
Autoimmun 34: 1-6. 
  41 
72. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, et al. (1986) Effects of 
transforming growth factor beta on the functions of natural killer cells: depressed 
cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916-
3920. 
73. mi Lee H, Kim K-S, Kim J (2014) A comparative study of the effects of inhibitory 
cytokines on human natural killer cells and the mechanistic features of transforming 
growth factor-beta. Cell Immunol 290: 52-61. 
74. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, et al. (1993) Interleukin 10 
(IL-10) inhibits human lymphocyte interferon gamma-production by suppressing 
natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178: 
1041-1048. 
75. Nakamoto N, Kanai T (2014) Role of Toll-Like Receptors in Immune Activation and 
Tolerance in the Liver. Front Immunol 5: 221. 
76. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, et al. (1999) Plasmacytoid 
monocytes migrate to inflamed lymph nodes and produce large amounts of type I 
interferon. Nat Med 5: 919-923. 
77. Plesa G, McKenna PM, Schnell MJ, Eisenlohr LC (2006) Immunogenicity of Cytopathic 
and Noncytopathic Viral Vectors. J Virol 80: 6259-6266. 
78. DeLeve LD (2013) Liver sinusoidal endothelial cells and liver regeneration. J Clin Invest 
123: 1861-1866. 
79. Klotz O, Belt TH (1930) Regeneration of Liver and Kidney Following Yellow Fever. The 
American journal of pathology 6: 689-697. 
80. Friedman SL (2008) Mechanisms of Hepatic Fibrogenesis. Gastroenterology 134: 1655-
1669. 
81. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, et al. (1996) Interferon gamma 
decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver 
fibrosis. Hepatology 23: 1189-1199. 
82. Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, et al. (2015) Daclatasvir and 
asunaprevir treatment improves liver function parameters and reduces liver fibrosis 
markers in chronic hepatitis C patients. Hepatology Research: Epub ahead of print. 
83. Casado JL, Quereda C, Moreno A, Pérez‐Elías MJ, Martí‐Belda P, et al. (2013) Regression 
of liver fibrosis is progressive after sustained virological response to HCV therapy in 
patients with hepatitis C and HIV coinfection. J Viral Hepat 20: 829-837. 
84. Li DK, Chung RT (2015) Impact of hepatitis C virus eradication on hepatocellular 
carcinogenesis. Cancer 121: 2874-2882. 
85. Hiramatsu N, Oze T, Takehara T (2015) Suppression of hepatocellular carcinoma 
development in hepatitis C patients given interferon‐based antiviral therapy. 
Hepatology Research 45: 152-161. 
86. Russo MW (2010) Antiviral therapy for hepatitis C is associated with improved clinical 
outcomes in patients with advanced fibrosis. Expert Rev Gastroenterol Hepatol 4: 
535-539. 
87. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc RSL B, Biol 
sciences 147: 258-267. 
88. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, et al. (1999) The 
nature of the principal type 1 interferon-producing cells in human blood. Science 284: 
1835-1837. 
89. Hoffmann H-H, Schneider WM, Rice CM (2015) Interferons and viruses: an evolutionary 
arms race of molecular interactions. Trends Immunol 36: 124-138. 
90. Kato T, Minagawa T (1981) Enhancement of Cytotoxicity of Human Peripheral Blood 
Lymphocytes by Interferon. Microbiology and Immunology 25: 837-845. 
 42 
91. Heim MH (2013) 25 years of interferon-based treatment of chronic hepatitis C: an epoch 
coming to an end. Nat Rev Immunol 13: 535-542. 
92. Isorce N, Lucifora J, Zoulim F, Durantel D (2015) Immune-modulators to combat 
hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic 
strategies. Antiviral Res 122: 69-81. 
93. Manzoor S (2015) Hepatitis B virus therapy: What’s the future holding for us? World J 
Gastroenterol 21: 12558-12575. 
94. Yurdaydin C, Idilman R (2015) Therapy of Delta Hepatitis. Cold Spring Harb Perspect 
Med 5: a021543. 
95. de Padilla CM, Niewold TB (2016) The type I interferons: Basic concepts and clinical 
relevance in immune-mediated inflammatory diseases. Gene 576: 14-21. 
96. Schreiber G, Piehler J (2015) The molecular basis for functional plasticity in type I 
interferon signaling. Trends Immunol 36: 139-149. 
97. Herberman RB, Nunn ME, Lavrin DH (1975) Natural cytotoxic reactivity of mouse 
lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity 
and specificity. International Journal of Cancer 16: 216-229. 
98. Kiessling R, Klein E, Pross H, Wigzell H (1975) „Natural”  killer cells in the mouse. II. 
Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of 
the killer cell. Eur J Immunol 5: 117-121. 
99. Lanier LL, Testi R, Bindl J, Phillips JH (1989) Identity of Leu-19 (CD56) leukocyte 
differentiation antigen and neural cell adhesion molecule. J Exp Med 169: 2233-2238. 
100. Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, et al. (1985) Generation of 
monoclonal antibodies to a human natural killer clone. Characterization of two 
natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large 
granular lymphocytes. J Clin Invest 75: 932-943. 
101. Griffin JD, Hercend T, Beveridge R, Schlossman SF (1983) Characterization of an 
antigen expressed by human natural killer cells. J Immunol 130: 2947-2951. 
102. Abo T, Cooper MD, Balch CM (1982) Characterization of HNK-1+ (Leu-7) human 
lymphocytes. I. Two distinct phenotypes of human NK cells with different cytotoxic 
capability. J Immunol 129: 1752-1757. 
103. Abo T, Balch CM (1981) A differentiation antigen of human NK and K cells identified by 
a monoclonal antibody (HNK-1). J Immunol 127: 1024-1029. 
104. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH (1986) The relationship of CD16 
(Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK 
cells and cytotoxic T lymphocytes. J Immunol 136: 4480-4486. 
105. Wu C, Li B, Lu R, Koelle SJ, Yang Y, et al. (2014) Clonal Tracking of Rhesus Macaque 
Hematopoiesis Highlights a Distinct Lineage Origin for Natural Killer Cells. Cell Stem 
Cell 14: 486-499. 
106. Mace EM, Hsu AP, Monaco-Shawver L, Makedonas G, Rosen JB, et al. (2013) Mutations 
in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) 
subset. Blood 121: 2669-2677. 
107. Luetke-Eversloh M, Killig M, Romagnani C (2013) Signatures of Human NK Cell 
Development and Terminal Differentiation. Front Immunol 4: 499. 
108. Renoux VM, Zriwil A, Peitzsch C, Michaëlsson J, Friberg D, et al. (2015) Identification of 
a Human Natural Killer Cell Lineage-Restricted Progenitor in Fetal and Adult Tissues. 
Immunity 43: 394-407. 
109. Scheiter M, Lau U, van Ham M, Bulitta B, Grobe L, et al. (2013) Proteome analysis of 
distinct developmental stages of human natural killer (NK) cells. Mol Cell Proteomics 
12: 1099-1114. 
  43 
110. Park BG, Park C-J, Jang S, Chi H-S, Kim D-Y, et al. (2015) Reconstitution of lymphocyte 
subpopulations after hematopoietic stem cell transplantation: comparison of 
hematologic malignancies and donor types in event-free patients. Leuk Res 39: 1334-
1341. 
111. Waggoner SN, Reighard SD, Gyurova IE, Cranert SA, Mahl SE, et al. (2016) Roles of 
natural killer cells in antiviral immunity. Curr Opin Virol 16: 15-23. 
112. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, et al. (2010) Expression 
patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell 
differentiation uncoupled from NK-cell education. Blood 116: 3853-3864. 
113. Cichocki F, Schlums H, Theorell J, Tesi B, Miller JS, et al. (2015) Diversification and 
Functional Specialization of Human NK Cell Subsets. Curr Top Microbiol Immunol: 
Epub ahead of print. 
114. Hu PF, Hultin LE, Hultin P, Hausner MA, Hirji K, et al. (1995) Natural killer cell 
immunodeficiency in HIV disease is manifest by profoundly decreased numbers of 
CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low 
lytic activity. JAIDS 10: 331-340. 
115. Gonzalez VD, Falconer K, Michaëlsson J, Moll M, Reichard O, et al. (2008) Expansion of 
CD56− NK cells in chronic HCV/HIV-1 co-infection: Reversion by antiviral 
treatment with pegylated IFNα and ribavirin. Clinical Immunology 128: 46-56. 
116. Bjorkstrom NK, Ljunggren HG, Sandberg JK (2010) CD56 negative NK cells: origin, 
function, and role in chronic viral disease. Trends Immunol 31: 401-406. 
117. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, et al. (2012) The transcription factors T-
bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 36: 
55-67. 
118. Knox JJ, Cosma GL, Betts MR, McLane LM (2014) Characterization of T-bet and eomes 
in peripheral human immune cells. Front Immunol 5: 217. 
119. Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, et al. (2014) T-bet and Eomes instruct 
the development of two distinct natural killer cell lineages in the liver and in the bone 
marrow. J Exp Med 211: 563-577. 
120. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, et al. (2012) Rapid development of 
exhaustion and down-regulation of eomesodermin limit the antitumor activity of 
adoptively transferred murine natural killer cells. Blood 119: 5758-5768. 
121. Ljunggren HG, Kärre K (1990) In search of the 'missing self': MHC molecules and NK 
cell recognition. Immunology today 11: 237-244. 
122. Lanier LL (1997) Natural Killer Cells: From No Receptors to Too Many. Immunity 6: 
371-378. 
123. Kruse PH, Matta J, Ugolini S, Vivier E (2013) Natural cytotoxicity receptors and their 
ligands. Immunol Cell Biol 92: 221-229. 
124. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling natural killer 
cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 
31: 227-258. 
125. Bryceson YT, Ljunggren HG, Long EO (2009) Minimal requirement for induction of 
natural cytotoxicity and intersection of activation signals by inhibitory receptors. 
Blood 114: 2657-2666. 
126. Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, et al. (2011) Molecular 
mechanisms of natural killer cell activation. J Innate Immun 3: 216-226. 
127. Cichocki F, Miller JS, Anderson SK, Bryceson YT (2013) Epigenetic regulation of NK cell 
differentiation and effector functions. Front Immunol 4: 55. 
 44 
128. Luetke-Eversloh M, Cicek BB, Siracusa F, Thom JT, Hamann A, et al. (2014) NK cells 
gain higher IFN-gamma competence during terminal differentiation. Eur J Immunol 
44: 2074-2084. 
129. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, et al. (2013) 
Genetic and environmental determinants of human NK cell diversity revealed by 
mass cytometry. Sci Transl Med 5: 208ra145. 
130. Strauss-Albee DM, Fukuyama J, Liang EC, Yao Y, Jarrell JA, et al. (2015) Human NK cell 
repertoire diversity reflects immune experience and correlates with viral susceptibility. 
Sci Transl Med 7: 297ra115. 
131. Yokoyama WM, Kim S (2006) Licensing of natural killer cells by self‐major 
histocompatibility complex class I. Immunol Rev 214: 143-154. 
132. Nash WT, Teoh J, Wei H, Gamache A, Brown MG (2014) Know Thyself: NK-Cell 
Inhibitory Receptors Prompt Self-Tolerance, Education, and Viral Control. Front 
Immunol 5: 175. 
133. Brodin P, Höglund P (2008) Beyond licensing and disarming: A quantitative view on 
NK‐cell education. Eur J Immunol 38: 2934-2937. 
134. Goodridge JP, Önfelt B, Malmberg KJ (2015) Newtonian cell interactions shape natural 
killer cell education. Immunol Rev 267: 197-213. 
135. Orr MT, Murphy WJ, Lanier LL (2010) 'Unlicensed' natural killer cells dominate the 
response to cytomegalovirus infection. Nat Immunol 11: 321-327. 
136. Manser AR, Weinhold S, Uhrberg M (2015) Human KIR repertoires: shaped by genetic 
diversity and evolution. Immunol Rev 267: 178-196. 
137. Williams N, Kubota A, Bennett M, Kumar V, Takei F (2000) Clonal analysis of NK cell 
development from bone marrow progenitors in vitro: orderly acquisition of receptor 
gene expression. Eur J Immunol 30: 2074-2082. 
138. Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH (2009) NK Cell 
Responsiveness Is Tuned Commensurate with the Number of Inhibitory Receptors 
for Self-MHC Class I: The Rheostat Model. J Immunol 182: 4572-4580. 
139. Huse M, Catherine Milanoski S, Abeyweera TP (2013) Building tolerance by dismantling 
synapses: inhibitory receptor signaling in natural killer cells. Immunol Rev 251: 143-
153. 
140. Dustin ML, Long EO (2010) Cytotoxic immunological synapses. Immunol Rev 235: 24-
34. 
141. Orange JS (2007) The lytic NK cell immunological synapse and sequential steps in its 
formation. Advances in Experimental Medicine and Biology 601: 225-233. 
142. McCormack R, Podack ER (2015) Perforin-2/Mpeg1 and other pore-forming proteins 
throughout evolution. J Leukoc Biol 98: 761-768. 
143. Voskoboinik I, Whisstock JC, Trapani JA (2015) Perforin and granzymes: function, 
dysfunction and human pathology. Nat Rev Immunol 15: 388-400. 
144. Wyllie AH, Kerr JFR, Currie AR (1973) Cell death in the normal neonatal rat adrenal 
cortex. The Journal of Pathology 111: 255-261. 
145. Green DR, Llambi F (2015) Cell Death Signaling. Cold Spring Harb Perspect Biol 7: 
a006080. 
146. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, et al. (1998) Natural Killer (NK) 
Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature 
and Mature Primary Human NK Cells. J Exp Med 188: 2375-2380. 
147. Herberman RB, Bartram S, Haskill JS, Nunn M, Holden HT, et al. (1977) Fc receptors on 
mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol 
119: 322-326. 
  45 
148. Isitman G, Lisovsky I, Tremblay-McLean A, Parsons MS, Shoukry NH, et al. (2015) 
Natural killer cell education does not affect the magnitude of granzyme B delivery to 
target cells by antibody-dependent cellular cytotoxicity. AIDS 29: 1433-1443. 
149. Horowitz A, Stegmann KA, Riley EM (2011) Activation of natural killer cells during 
microbial infections. Front Immunol 2: 88. 
150. Waggoner SN, Cornberg M, Selin LK, Welsh RM (2012) Natural killer cells act as 
rheostats modulating antiviral T cells. Nature 481: 394-398. 
151. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, et al. (2012) Natural killer cell 
activation enhances immune pathology and promotes chronic infection by limiting 
CD8+ T-cell immunity. PNAS 109: 1210-1215. 
152. Xu HC, Grusdat M, Pandyra AA, Polz R, Huang J, et al. (2014) Type I interferon protects 
antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 40: 949-960. 
153. Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, et al. (2014) Type I 
interferons protect T cells against NK cell attack mediated by the activating receptor 
NCR1. Immunity 40: 961-973. 
154. Wilson JL, Heffler LC, Charo J, Scheynius A, Bejarano MT, et al. (1999) Targeting of 
human dendritic cells by autologous NK cells. J Immunol 163: 6365-6370. 
155. Carbone E, Terrazzano G, Ruggiero G, Zanzi D, Ottaiano A, et al. (1999) Recognition of 
autologous dendritic cells by human NK cells. Eur J Immunol 29: 4022-4029. 
156. Lister J (1867) On the Antiseptic Principle in the Practice of Surgery. BMJ 2: 246-248. 
157. Mackintosh JM (1955) Snow, the man and his times. Pro RSM 48: 1004-1007. 
158. [No authors listed] (1896) Edward Jenner: His Life, his Work, and his Writings. BMJ 1: 
1245-1261. 
159. Institute for Health Metrics and Evaluation. (2016); Available from www.healthdata.org 
160. Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, et al. (1994) Hepatitis B and C virus 
infection as risk factors for hepatocellular carcinoma in Chinese: A case‐control study. 
International Journal of Cancer 56: 619-621. 
161. El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. 
Gastroenterology 142: 1264-12730. 
162. World Health Organization. (2016); Available from www.who.int 
163. Busch K, Thimme R (2014) Natural history of chronic hepatitis B virus infection. Med 
Microbiol Immunol 204: 5-10. 
164. Gish RG, Given BD, Lai C-L, Locarnini SA, Lau J, et al. (2015) Chronic hepatitis B: 
Virology, natural history, current management and a glimpse at future opportunities. 
Antiviral Res 121: 47-58. 
165. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, et al. (2014) Hepatitis B and D 
Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-
Specific Entry into Hepatocytes. Gastroenterology 146: 1070-1083. 
166. Li H-C, Huang E-Y, Su P-Y, Wu S-Y, Yang C-C, et al. (2010) Nuclear Export and Import 
of Human Hepatitis B Virus Capsid Protein and Particles. PLoS Pathogens 6. 
167. Beck J, Nassal M (2007) Hepatitis B virus replication. World J Gastroenterol 13: 48-64. 
168. Levrero M, Pollicino T, Petersen J, Belloni L, Rainmondo G, et al (2009) Control of 
cccDNA function in hepatitis B infection. J Hepatol 51: 581-592 
169. Liang K-H, Hsu C-W, Chang M-L, Chen Y-C, Lai M-W, et al. (2015) Peginterferon Is 
Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in 
Chronic Hepatitis B. JID: Epub ahead of print. 
170. Clark DN, Hu J (2015) Hepatitis B virus reverse transcriptase – Target of current 
antiviral therapy and future drug development. Antiviral Res 123: 132-137. 
171. Yim H, Hwang S (2013) Options for the management of antiviral resistance during 
hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol 19: 195-209. 
 46 
172. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, et al. (2009) The Size of 
the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection. J Virol 
83: 9652-9662. 
173. Balmasova IP, Yushchuk ND, Mynbaev OA, Alla NR, Malova ES, et al. (2014) 
Immunopathogenesis of chronic hepatitis B. World J Gastroenterol 20: 14156-14171. 
174. Zhang YY, Hu KQ (2015) Rethinking the pathogenesis of hepatitis B virus (HBV) 
infection. J Med Virol 87: 1989-1999. 
175. Yang PL, Althage A, Chung J, Maier H, Wieland S, et al. (2010) Immune effectors 
required for hepatitis B virus clearance. PNAS 107: 798-802. 
176. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, et al. (2007) Cytokines 
induced during chronic hepatitis B virus infection promote a pathway for NK cell–
mediated liver damage. J Exp Med 204: 667-680. 
177. Schuch A, Hoh A, Thimme R (2014) The Role of Natural Killer Cells and CD8+ T Cells 
in Hepatitis B Virus Infection. Front Immunol 5: 258. 
178. van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HGM, et al. (2004) 
Functional impairment of myeloid and plasmacytoid dendritic cells of patients with 
chronic hepatitis B. Hepatology 40: 738-746. 
179. Ferrari C, Mondelli MU, Penna A, Fiaccadori F, Chisari FV (1987) Functional 
characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper 
T cell lines. J Immunol 139: 539-544. 
180. Inoue M, Kakumu S, Yoshioka K, Tsutsumi Y, Wakita T, et al. (1989) Hepatitis B core 
antigen-specific IFN-gamma production of peripheral blood mononuclear cells in 
patients with chronic hepatitis B virus infection. J Immunol 142: 4006-4011. 
181. Marinos G, Torre F, Chokshi S, Hussain M, Clarke BE, et al. (1995) Induction of T‐
helper cell response to hepatitis B core antigen in chronic hepatitis B: A major factor 
in activation of the host immune response to the hepatitis B virus. Hepatology 22: 
1040-1049. 
182. Karimi-Googheri M, Arababadi M (2014) TLR3 plays significant roles against hepatitis B 
virus. Mol Biol Rep 41: 3279-3286. 
183. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, et al. (2003) CD8(+) T cells 
mediate viral clearance and disease pathogenesis during acute hepatitis B virus 
infection. J Virol 77: 68-76. 
184. Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, et al. (2016) Interferon-γ and Tumor 
Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, 
Without Cytolysis. Gastroenterology 150: 194-205. 
185. Sun C, Sun H, Zhang C, Tian Z (2015) NK cell receptor imbalance and NK cell 
dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol 12: 
292-302. 
186. Zheng S-JJ, Wang P, Tsabary G, Chen YH (2004) Critical roles of TRAIL in hepatic cell 
death and hepatic inflammation. J Clin Invest 113: 58-64. 
187. Peppa D, Gill US, Reynolds G, Easom N, Pallett LJ, et al. (2013) Up-regulation of a death 
receptor renders antiviral T cells susceptible to NK cell–mediated deletion. J Exp Med 
210: 99-114. 
188. Peppa D, Micco L, Javaid A, Kennedy PTF, Schurich A, et al. (2010) Blockade of 
Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic 
Hepatitis B Virus Infection. PLoS Pathogens 6: e1001227. 
189. Du J, Liang X, Liu Y, Qu Z, Gao L, et al. (2008) Hepatitis B virus core protein inhibits 
TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death & 
Differentiation 16: 219-229. 
  47 
190. Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, et al. (1977) Immunofluorescence 
detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B 
virus in liver and in serum of HBsAg carriers. Gut 18: 997-1003. 
191. Romeo R (2015) Hepatitis delta virus: Making the point from virus isolation up to 2014. 
World J Hepatol 7: 2389-2395. 
192. Verme G, Brunetto M, Oliveri F, Baldi M, Forzani B, et al. (1991) Role of hepatitis delta 
virus infection in hepatocellular carcinoma. Dig Dis Sci 36: 1134-1136. 
193. Flores R, Ruiz-Ruiz S, Serra P (2012) Viroids and hepatitis delta virus. Semin Liver Dis 
32: 201-210. 
194. Taylor J, Pelchat M (2010) Origin of hepatitis δ virus. Future Microbiol 5: 393-402. 
195. Negro F (2014) Hepatitis D Virus Coinfection and Superinfection. Cold Spring Harb 
Perspect Med 4: a021550. 
196. Kos A, Dijkema R, Arnberg AC, van der Meide PH, Schellekens H (1986) The hepatitis 
delta (δ) virus possesses a circular RNA. Nature 323: 558-560. 
197. Alfaiate D, Dény P, Durantel D (2015) Hepatitis delta virus: From biological and medical 
aspects to current and investigational therapeutic options. Antiviral Res 122: 112-129. 
198. Taylor JM (2015) Hepatitis D Virus Replication. Cold Spring Harb Perspect Med 5: 
a021568. 
199. Ciancio A, Rizzetto M (2014) Chronic hepatitis D at a standstill: where do we go from 
here? Nat Rev Gastroenterol & Hepatol 11: 68-71. 
200. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, et al. (2014) Late HDV 
RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta. 
Hepatology 60: 87-97. 
201. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, et al. (2011) 
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 
364: 322-331. 
202. Grabowski J, Wedemeyer H (2010) Hepatitis Delta: Immunopathogenesis and Clinical 
Challenges. Digestive Diseases 28: 133-138. 
203. Pugnale P, Pazienza V, Guilloux K, Negro F (2009) Hepatitis delta virus inhibits alpha 
interferon signaling. Hepatology 49: 398-406. 
204. Actis GC, Maran E, Bonino F, Saracco G, Rosina F, et al. (1987) Patterns of natural killer 
cell function activation in response to interferon in chronic HBsAG positive hepatitis: 
relationship with the state of viral infection and with the early clinical response. 
Journal of biological regulators and homeostatic agents 1: 45-50. 
205. Actis GC, Maran E, Saracco G, Rosina F, Baldi M, et al. (1987) Natural killer cell function 
during interferon treatment of delta hepatitis. Progress in clinical and biological 
research 234: 305-308. 
206. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV (1975) Transfusion-
associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 292: 767-770. 
207. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, et al. (2006) Hepatitis C 
Virus Entry Depends on Clathrin-Mediated Endocytosis. J Virol 80: 6964-6972. 
208. Douam F, Lavillette D, Cosset F-L (2015) The Mechanism of HCV Entry into Host Cells. 
Prog Mol Biol Transl Sci 129: 63-107. 
209. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, et al. (2003) Cell Entry of 
Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin 
and the SR-B1 Scavenger Receptor. Journal of Biological Chemistry 278: 41624-41630. 
210. Kim C, Chang K-M (2012) Hepatitis C virus: virology and life cycle. Clin Mol Hepatol 
19: 17-25. 
211. Pawlotsky J-M, Feld JJ, Zeuzem S, Hoofnagle JH (2015) From non-A, non-B hepatitis to 
hepatitis C virus cure. J Hepatol 62: 84-99. 
 48 
212. Pawlotsky JM (2013) Treatment of chronic hepatitis C: current and future. Curr Top 
Microbiol Immunol 369: 321-342. 
213. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. (2014) 
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. 
N Engl J Med 370: 211-221. 
214. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, et al. (2014) Phase 2b trial of 
interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370: 222-232. 
215. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, et al. (2015) Sofosbuvir and 
Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 373: 
2618-2628. 
216. Solbach P, Wedemeyer H (2015) The New Era of Interferon-Free Treatment of Chronic 
Hepatitis C. Viszeralmedizin 31: 290-296. 
217. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in 
IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401. 
218. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferon-induced gene 
expression is a stronger predictor of treatment response than IL28B genotype in 
patients with hepatitis C. Gastroenterology 140: 1021-1031. 
219. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, et al. (2012) Hepatic Cell–Type 
Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B 
Genotype. Gastroenterology 142: 1122-11310. 
220. Makowska Z, Heim MH (2012) Interferon signaling in the liver during hepatitis C virus 
infection. Cytokine 59: 460-466. 
221. Florentin J, Aouar B, Dental C, Thumann C, Firaguay G, et al. (2012) HCV glycoprotein 
E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by 
plasmacytoid dendritic cells. Blood 120: 4544-4551. 
222. Dental C, Florentin J, Aouar B, Gondois-Rey F, Durantel D, et al. (2012) Hepatitis C 
virus fails to activate NF-κB signaling in plasmacytoid dendritic cells. J Virol 86: 1090-
1096. 
223. Qashqari H, Al-Mars A, Chaudhary A, Abuzenadah A, Damanhouri G, et al. (2013) 
Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced 
interferon resistance. Infection, Genetics and Evolution 19: 113-119. 
224. Heim MH, Thimme R (2014) Innate and adaptive immune responses in HCV infections. 
J Hepatol 61: S14-25. 
225. Klenerman P, Thimme R (2012) T cell responses in hepatitis C: the good, the bad and the 
unconventional. Gut 61: 1226-1234. 
226. Gardiner CM (2015) NK cell function and receptor diversity in the context of HCV 
infection. Front Microbiol 6: 1061. 
227. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. (2004) HLA and NK cell 
inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872-
874. 
228. Kokordelis P, Krämer B, Körner C, Boesecke C, Voigt E, et al. (2014) An effective 
interferon-gamma-mediated inhibition of hepatitis C virus replication by natural 
killer cells is associated with spontaneous clearance of acute hepatitis C in human 
immunodeficiency virus-positive patients. Hepatology 59: 814-827. 
229. Holder KA, Stapleton SN, Gallant ME, Russell RS, Grant MD (2013) Hepatitis C virus-
infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. J Immunol 
191: 3308-3318. 
230. Pembroke T, Christian A, Jones E, Hills RK, Wang EC, et al. (2014) The paradox of 
NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but 
in-vivo resistance to interferon α treatment. Gut 63: 515-524. 
  49 
231. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, et al. (1981) Pneumocystis 
carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: 
evidence of a new acquired cellular immunodeficiency. N Engl J Med 305: 1425-1431. 
232. Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, et al. (2014) The early spread 
and epidemic ignition of HIV-1 in human populations. Science 346: 56-61. 
233. Saxinger WC, Levine PH, Dean AG, de Thé G, Lange-Wantzin G, et al. (1985) Evidence 
for exposure to HTLV-III in Uganda before 1973. Science 227: 1036-1038. 
234. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. (1983) Isolation 
of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency 
syndrome (AIDS). Science 220: 868-871. 
235. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The 
CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. 
Nature 312: 763-767. 
236. Alkhatib G (2009) The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 4: 96-103. 
237. Valerie K, Delers A, Bruck C, Thiriart C, Rosenberg H, et al. (1988) Activation of human 
immunodeficiency virus type 1 by DNA damage in human cells. Nature 333: 78-81. 
238. Freed EO (2015) HIV-1 assembly, release and maturation. Nat Rev Microbiol 13: 484-
496. 
239. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, et al. (1987) Genome 
organization and transactivation of the human immunodeficiency virus type 2. 
Nature 326: 662-669. 
240. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, et al. (1994) Slower 
heterosexual spread of HIV-2 than HIV-1. Lancet 343: 943-946. 
241. de Silva TI, Cotten M, Rowland-Jones SL (2008) HIV-2: the forgotten AIDS virus. 
Trends Microbiol 16: 588-595. 
242. Vella S, Schwartländer B, Sow S, Eholie S, Murphy RL (2012) The history of 
antiretroviral therapy and of its implementation in resource-limited areas of the 
world. AIDS 26: 1231-1241. 
243. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for 
HIV. (2015) World Health Organization. 
244. Barouch DH, Deeks SG (2014) Immunologic strategies for HIV-1 remission and 
eradication. Science 345: 169-174. 
245. Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, et al. (2009) Long-Term Control 
of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. N Engl J Med 360: 692-
698. 
246. Mugo NR, Ngure K, Kiragu M, Irungu E, Kilonzo N (2016) The preexposure prophylaxis 
revolution; from clinical trials to programmatic implementation. Curr Opin HIV 
AIDS 11: 80-86. 
247. Pöhlmann S, Leslie GJ, Edwards TG, Macfarlan T, Reeves JD, et al. (2001) DC-SIGN 
interactions with human immunodeficiency virus: virus binding and transfer are 
dissociable functions. J Virol 75: 10523-10526. 
248. Engering A, Vliet SJ, Geijtenbeek TBH, Kooyk Y (2002) Subset of DC-SIGN+ dendritic 
cells in human blood transmits HIV-1 to T lymphocytes. Blood 100: 1780-1786. 
249. Gummuluru S, KewalRamani VN, Emerman M (2002) Dendritic cell-mediated viral 
transfer to T cells is required for human immunodeficiency virus type 1 persistence in 
the face of rapid cell turnover. J Virol 76: 10692-10701. 
250. Burleigh L, Lozach P-YY, Schiffer C, Staropoli I, Pezo V, et al. (2006) Infection of 
dendritic cells (DCs), not DC-SIGN-mediated internalization of human 
immunodeficiency virus, is required for long-term transfer of virus to T cells. J Virol 
80: 2949-2957. 
 50 
251. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, et al. (2009) Induction of a Striking 
Systemic Cytokine Cascade prior to Peak Viremia in Acute Human 
Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed 
Responses in Acute Hepatitis B and C Virus Infections. J Virol 83: 3719-3733. 
252. Leeansyah E, Malone DF, Anthony DD, Sandberg JK (2013) Soluble biomarkers of HIV 
transmission, disease progression and comorbidities. Curr Opin HIV AIDS 8: 117-
124. 
253. Doyle T, Goujon C, Malim MH (2015) HIV-1 and interferons: who's interfering with 
whom? Nat Rev Microbiol 13: 403-413. 
254. Altfeld M, Jr M (2015) Innate immunity against HIV-1 infection. Nat Immunol 16: 554-
562. 
255. Cheng X, Ratner L (2014) HIV-2 Vpx protein interacts with interferon regulatory factor 
5 (IRF5) and inhibits its function. J Biol Chem 289: 9146-9157. 
256. Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, et al. (1996) Efficient lysis of 
human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J 
Virol 70: 5799-5806. 
257. Famularo G, Moretti S, Marcellini S, Nucera E, De Simone C (1997) CD8 lymphocytes in 
HIV infection: helpful and harmful. J clin lab immunol 49: 15-32. 
258. Zarling JM, Ledbetter JA, Sias J, Fultz P, Eichberg J, et al. (1990) HIV-infected humans, 
but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected 
CD4+ cells. J Immunol 144: 2992-2998. 
259. Ndyopadhyay S, Ziegner U, Campbell DE, Miller DS, Hoxie JA, et al. (2008) Natural 
killer cell-mediated lysis of T cell lines chronically infected with HIV-1. Clinical & 
Experimental Immunology 79: 430-435. 
260. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, et al. (2014) Cell death by 
pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505: 509-514. 
261. Galloway N, Doitsh G, Monroe KM, Yang Z, Muñoz-Arias I, et al. (2015) Cell-to-Cell 
Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-
Derived CD4 T Cells. Cell Rep 12: 1555-1563. 
262. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, et al. (2002) Selective loss 
of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus 
infection. J Virol 76: 7528-7534. 
263. Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, et al. (2009) Severe 
functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells 
retained during chronic HIV-1 infection. Eur J Immunol 39: 902-911. 
264. Gonzalez VD, Landay AL, Sandberg JK (2010) Innate immunity and chronic immune 
activation in HCV/HIV-1 co-infection. Clin Immunol 135: 12-25. 
265. Alter G, Malenfant JM, Delabre RM, Burgett NC, Yu XG, et al. (2004) Increased natural 
killer cell activity in viremic HIV-1 infection. J Immunol 173: 5305-5311. 
266. Kuri-Cervantes L, de Oca GS, Avila-Rios S, Hernandez-Juan R, Reyes-Teran G (2014) 
Activation of NK cells is associated with HIV-1 disease progression. J Leukoc Biol 96: 
7-16. 
267. Tomescu C, Chehimi J, Maino VC, Montaner LJ (2007) NK cell lysis of HIV-1-infected 
autologous CD4 primary T cells: requirement for IFN-mediated NK activation by 
plasmacytoid dendritic cells. J Immunol 179: 2097-2104. 
268. Tomescu C, Mavilio D, Montaner LJ (2015) Lysis of HIV-1-infected autologous CD4+ 
primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D. 
AIDS 29: 1767-1773. 
  51 
269. Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, et al. (2013) 
CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector 
function during HIV-1 infection. Retrovirology 10: 158. 
270. Nuvor SV, van der Sande M, Rowland-Jones S, Whittle H, Jaye A (2006) Natural killer 
cell function is well preserved in asymptomatic human immunodeficiency virus type 2 
(HIV-2) infection but similar to that of HIV-1 infection when CD4 T-cell counts fall. J 
Virol 80: 2529-2538. 
271. Kallal LE, Biron CA (2013) Changing partners at the dance: Variations in STAT 
concentrations for shaping cytokine function and immune responses to viral 
infections. JAKSTAT 2: e23504. 
272. Welsh RM, Waggoner SN (2013) NK cells controlling virus-specific T cells: Rheostats for 
acute vs. persistent infections. Virology 435: 37-45. 
273. Béziat V, Liu LL, Malmberg J-AA, Ivarsson MA, Sohlberg E, et al. (2013) NK cell 
responses to cytomegalovirus infection lead to stable imprints in the human KIR 
repertoire and involve activating KIRs. Blood 121: 2678-2688. 
274. Zheng Q, Zhu YY, Chen J, Ye YB, Li JY, et al. (2015) Activated natural killer cells 
accelerate liver damage in patients with chronic hepatitis B virus infection. Clin Exp 
Immunol 180: 499-508. 
275. Younas M, Psomas C, Reynes J, Corbeau P (2015) Immune activation in the course of 
HIV‐1 infection: Causes, phenotypes and persistence under therapy. HIV Med: Epub 
ahead of print. 
276. Zapata HJ, Shaw AC (2014) Aging of the human innate immune system in HIV 
infection. Curr Opin Immunol 29: 127-136. 
277. Longenecker CT, Sullivan C, Baker JV (2015) Immune activation and cardiovascular 
disease in chronic HIV infection. Curr Opin HIV AIDS: Epub ahead of print. 
278. Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, et al. (2015) 
Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through 
prolonged synapse time. J Exp Med 212: 307-317. 
279. Lichtfuss GF, Cheng W-J, Farsakoglu Y, Paukovics G, Rajasuriar R, et al. (2012) 
Virologically Suppressed HIV Patients Show Activation of NK Cells and Persistent 
Innate Immune Activation. J Immunol 189: 1491-1499. 
280. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW (1996) Progressive 
liver injury in chronic hepatitis C infection correlates with increased intrahepatic 
expression of Th1‐associated cytokines. Hepatology 24: 759-765. 
281. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, et al. (2011) Host response to 
translocated microbial products predicts outcomes of patients with HBV or HCV 
infection. Gastroenterology 141: 1220-1230. 
282. Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, et al. (2014) 
Immune activation and microbial translocation in liver disease progression in 
HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC 
Infectious Diseases 14: 79. 
283. Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, et al. (2015) Soluble CD163 is an 
indicator of liver inflammation and fibrosis in patients chronically infected with the 
hepatitis B virus. J Viral Hepat 22: 427-432. 
284. Sandler NG, Douek DC (2012) Microbial translocation in HIV infection: causes, 
consequences and treatment opportunities. Nat Rev Microbiol 10: 655-666. 
285. Su GL, Dorko K, Strom SC, Nüssler AK, Wang SC (1999) CD14 expression and 
production by human hepatocytes. J Hepatol 31: 435-442. 
 52 
286. Ogawa Y, Imajo K, Yoneda M, Kessoku T, Tomeno W, et al. (2013) Soluble CD14 levels 
reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One 8: 
e65211. 
287. Paquin-Proulx D, Santos BA, Carvalho KI, Toledo-Barros M, Barreto de Oliveira AK, et 
al. (2013) IVIg immune reconstitution treatment alleviates the state of persistent 
immune activation and suppressed CD4 T cell counts in CVID. PLoS One 8: e75199. 
288. Anthony DD, Conry SJ, Medvik K, Sandhya Rani MR, Falck-Ytter Y, et al. (2012) 
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively 
associated with response to interferon/ribavirin therapy during HCV-HIV-1 
coinfection. JID 206: 969-973. 
289. Vassallo M, Mercié P, Cottalorda J, Ticchioni M, Dellamonica P (2012) The role of 
lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a 
systematic literature review. Virology Journal 9: 174. 
290. Nowroozalizadeh S, Månsson F, da Silva Z, Repits J, Dabo B, et al. (2010) Microbial 
translocation correlates with the severity of both HIV-1 and HIV-2 infections. JID 
201: 1150-1154. 
291. Vyboh K, Jenabian M-A, Mehraj V, Routy J-P (2015) HIV and the Gut Microbiota, 
Partners in Crime: Breaking the Vicious Cycle to Unearth New Therapeutic Targets. J 
Immunol Res 2015: 614127. 
292. Alter G, Jost S, Rihn S, Reyor LL, Nolan BE, et al. (2011) Reduced frequencies of 
NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may 
predict viral clearance. J Hepatol 55: 278-288. 
293. Kramer B, Korner C, Kebschull M, Glassner A, Eisenhardt M, et al. (2012) Natural killer 
p46High expression defines a natural killer cell subset that is potentially involved in 
control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 
56: 1201-1213. 
294. Zhao J, Li Y, Jin L, Zhang S, Fan R, et al. (2012) Natural Killer Cells Are Characterized by 
the Concomitantly Increased Interferon-γ and Cytotoxicity in Acute Resolved 
Hepatitis B Patients. PLoS One 7: e49135. 
295. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, et al. (2009) Natural killer 
cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus 
infections. Gastroenterology 137: 1151-1160. 
296. Meier UC, Owen RE, Taylor E, Worth A, Naoumov N, et al. (2005) Shared alterations in 
NK cell frequency, phenotype, and function in chronic human immunodeficiency 
virus and hepatitis C virus infections. J Virol 79: 12365-12374. 
297. Funaro A, Spagnoli GC, Ausiello CM, Alessio M, Roggero S, et al. (1990) Involvement of 
the multilineage CD38 molecule in a unique pathway of cell activation and 
proliferation. J Immunol 145: 2390-2396. 
298. O’Connor GM, Holmes A, Mulcahy F, Gardiner CM (2007) Natural Killer cells from 
long-term non-progressor HIV patients are characterized by altered phenotype and 
function. Clinical Immunology 124: 277-283. 
299. Maria A, Fogli M, Costa P, Murdaca G, Puppo F, et al. (2003) The impaired NK cell 
cytolytic function in viremic HIV‐1 infection is associated with a reduced surface 
expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J 
Immunol 33: 2410-2418. 
300. Leligdowicz A, Feldmann J, Jaye A, Cotten M, Dong T, et al. (2010) Direct relationship 
between virus load and systemic immune activation in HIV-2 infection. JID 201: 114-
122. 
  53 
301. Cosgrove C, Berger CT, Kroy DC, Cheney PC, Ghebremichael M, et al. (2014) Chronic 
HCV infection affects the NK cell phenotype in the blood more than in the liver. PLoS 
One 9: e105950. 
302. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, et al. (2013) Differential boosting of 
innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of 
chronic hepatitis B. J Hepatol 58: 225-233. 
303. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, et al. (2011) Early Changes 
in Natural Killer Cell Function Indicate Virologic Response to Interferon Therapy for 
Hepatitis C. Gastroenterology 141: 1231-1239. 
304. Nakamura I, Asano T, Asabe S, Ando M, Sano T, et al. (2015) Restoration of natural 
killer cell activity by pegylated interferon-alpha/ribavirin therapy in chronic hepatitis 
C patient. Hepatol Res 45: 107-112. 
305. Varchetta S, Mele D, Lombardi A, Oliviero B, Mantovani S, et al. (2015) Lack of Siglec-7 
expression identifies a dysfunctional natural killer cell subset associated with liver 
inflammation and fibrosis in chronic HCV infection. Gut: Epub ahead of print. 
306. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, et al. (2012) Early 
changes in interferon signaling define natural killer cell response and refractoriness to 
interferon-based therapy of hepatitis C patients. Hepatology 55: 39-48. 
307. Gonzalez VD, Falconer K, Bjorkstrom NK, Blom KG, Weiland O, et al. (2009) Expansion 
of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: 
correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 
183: 6612-6618. 
308. Kazankov K, Barrera F, Moller HJ, Bibby BM, Vilstrup H, et al. (2014) Soluble CD163, a 
macrophage activation marker, is independently associated with fibrosis in patients 
with chronic viral hepatitis B and C. Hepatology 60: 521-530. 
309. Dultz G, Gerber L, Zeuzem S, Sarrazin C, Waidmann O (2015) The macrophage 
activation marker CD163 is associated with IL28B genotype and hepatic inflammation 
in chronic hepatitis C virus infected patients. J Viral Hepat: Epub ahead of print. 
310. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B 
Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of 
Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology 139: 
120-129. 
311. Stegmann KA, Björkström NK, Veber H, Ciesek S, Riese P, et al. (2010) Interferon-
alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C 
virus infection. Gastroenterology 138: 1885-1897. 
312. Zhu Y, Qin B, Xiao C, Lu X, Chen L (2012) Cell-Type Specific Interferon Stimulated 
Gene Staining in Liver Underlies Response to Interferon Therapy in Chronic HBV 
Infected Patients. Dig Dis Sci 57: 2355-2361. 
313. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, et al. (2015) Successful Interferon-
Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell 
Function. Gastroenterology 149: 190-200. 
314. Spaan M, van Oord G, Kreefft K, Hou J, Hansen BE, et al. (2016) Immunological 
Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection 
Reveals Modulation of the Natural Killer Cell Compartment. JID 213: 216-223. 
 
